var title_f18_55_19312="Intrauterine balloon";
var content_f18_55_19312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Manual insertion of a Bakri balloon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19312=[""].join("\n");
var outline_f18_55_19312=null;
var title_f18_55_19313="Junctional nevus";
var content_f18_55_19313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Junctional nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flat junctional nevus with darker pigmentation in the center than at the periphery. This lesion is symmetric with a regular outline.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19313=[""].join("\n");
var outline_f18_55_19313=null;
var title_f18_55_19314="Endometrial cancer diagnosis and staging";
var content_f18_55_19314=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/55/19314/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19314/contributors\" id=\"au4486\">",
"       Lee-may Chen, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19314/contributors\" id=\"au4266\">",
"       Jonathan S Berek, MD, MMS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/55/19314/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19314/contributors\" id=\"se7382\">",
"       Barbara Goff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/55/19314/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19314/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19314/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?18/55/19314?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Endometrial cancer is a type of uterine cancer that involves the lining of the uterus (the endometrium). In the United States, endometrial cancer is the most common cancer of the female reproductive system. Fortunately, most women are diagnosed at an early stage (before the cancer has spread outside the uterus), when the disease can usually be cured with surgery alone. Endometrial cancer can occur in a woman of any age, although it is much more common after menopause.",
"    </p>",
"    <p>",
"     This article discusses the risk factors, symptoms, and diagnosis of the most common type of endometrial cancer, called endometrioid endometrial cancer. A separate article discusses the treatment of the endometrioid type of endometrial cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=see_link\">",
"      \"Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about endometrial cancer is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"      \"Endometrial carcinoma: Epidemiology and risk factors\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link\">",
"      \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      THE UTERUS",
"     </span>",
"    </p>",
"    <p>",
"     To understand how endometrial cancer develops, it is helpful to understand the structure of the uterus. The uterus is a pear-shaped organ located between the bladder and the rectum. The cervix connects the uterus to the vagina. The inside of the uterus has two layers. The thin inner layer is called the endometrium. The thick outer layer is composed of muscle and is called the myometrium (myo = muscle) (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In women who menstruate, the endometrium thickens every month in preparation for pregnancy. If the woman does not become pregnant, the endometrial lining is shed during the menstrual period. After menopause, when menstrual periods stop, the endometrial lining normally stops growing and shedding. In women who have endometrial cancer, the uterine lining develops abnormal cells.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ENDOMETRIAL CANCER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common sign of endometrial cancer is abnormal vaginal bleeding.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In a woman who is still having menstrual periods, abnormal bleeding is defined as bleeding between menstrual periods or heavy menstrual bleeding. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"        \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       In a postmenopausal woman,",
"       <strong>",
"        any vaginal bleeding",
"       </strong>",
"       is considered abnormal, even if it is only one drop of blood. This is especially true in women who are not taking postmenopausal hormone therapy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Women who take postmenopausal hormone therapy often have some vaginal bleeding in the first few months of treatment. However, if you are taking postmenopausal hormone therapy and you have bleeding, you should check with your doctor or nurse.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      ENDOMETRIAL CANCER DIAGNOSIS AND STAGING",
"     </span>",
"    </p>",
"    <p>",
"     Your doctor or nurse might recommend testing for endometrial cancer if you have abnormal bleeding. The most commonly used tests include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A test that is done in the office, called endometrial biopsy.",
"      </li>",
"      <li>",
"       A test that is done as a day surgery, called hysteroscopy with dilation and curettage. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"        \"Patient information: Dilation and curettage (D and C) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These tests take a sample of tissue from the lining of the uterus, called the endometrium. A doctor will examine the tissue with a microscope to see if there are signs of cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Tumor staging",
"     </span>",
"     &nbsp;&mdash;&nbsp;Once endometrial cancer is diagnosed, the next step is to determine its stage. Staging is a system used to describe the spread of a cancer. Endometrial cancer's stage is based on:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       How deeply the cancer has invaded the muscle wall of the uterus",
"      </li>",
"      <li>",
"       Whether there are signs that the cancer has spread to other organs on a physical exam, MRI of the abdomen and pelvis, chest X-ray, or other imaging tests",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Endometrial cancer stages range from stage I (cancer has not invaded beyond the lining of the uterus) to stage IV (the cancer has spread to distant organs, such as the liver). In general, lower stage cancers are less aggressive and require less treatment than do higher stage cancers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery is usually done to determine how deeply the cancer has invaded the muscle wall of the uterus. At the same time, the cancer can be treated by removing the uterus, ovaries, and fallopian tubes. Surgery is done in an operating room with general anesthesia, and most women stay in the hospital for several days after the surgery.",
"    </p>",
"    <p>",
"     Surgery can be done by making a vertical (up-and-down) or horizontal (left-to-right) incision in the abdomen, then examining the organs within the pelvis and abdomen for signs of cancer. This is called a laparotomy.",
"    </p>",
"    <p>",
"     In other cases, surgery can be done laparoscopically, which is done through small incisions in the abdomen. The surgeon uses a thin, lighted instrument with a camera (a laparoscope) to see inside the abdomen and remove tissues.",
"    </p>",
"    <p>",
"     The choice between laparotomy and laparoscopy depends on your situation and your surgeon's preference.",
"    </p>",
"    <p>",
"     During the surgery, the following procedures are performed:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The uterus and ovaries are removed (called total abdominal hysterectomy and bilateral salpingo-oophorectomy). This procedure is described in detail in a separate article. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"        \"Patient information: Abdominal hysterectomy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Fluid from the abdomen and any abnormal tissue in the pelvis or abdomen are evaluated to determine whether the cancer has spread outside of the uterus",
"      </li>",
"      <li>",
"       The lymph nodes surrounding the uterus are examined. One of the first places that endometrial cancer spreads to is the lymph nodes. Swelling of the legs (lymphedema) affects approximately 5 to 40 percent of women with endometrial cancer following removal of lymph nodes.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      If surgery is not possible",
"     </span>",
"     &nbsp;&mdash;&nbsp;If surgery is too risky, such as in elderly women and women with serious medical problems, radiation therapy alone may be recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ENDOMETRIAL CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of endometrial cancer depends on how likely it is that the cancer will come back after treatment. This risk is based on:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The stage of the cancer, which is based on what is found during surgery (see",
"       <a class=\"local\" href=\"#H5\">",
"        'Tumor staging'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       How aggressive the tumor appears (called the tumor grade) when the tissue is examined under a microscope. High-grade tumors are usually faster growing and more likely to spread than low-grade tumors.",
"      </li>",
"      <li>",
"       What type of cells make up the tumor (called cell histology). Some cell types have a higher risk of coming back after treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Depending on these characteristics, the cancer is said to have a low, intermediate, or high risk of coming back after surgery. These designations are used to decide which treatments, if any, are needed after surgery to decrease the risk of the cancer coming back.",
"    </p>",
"    <p>",
"     Endometrial cancer treatment is discussed in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=see_link\">",
"      \"Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PREGNANCY AND ENDOMETRIAL CANCER",
"     </span>",
"    </p>",
"    <p>",
"     Although cancer is more common in postmenopausal women, it can develop in younger women. A woman with endometrial cancer who would like to have a child in the future should discuss treatment options with her doctor. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=see_link&amp;anchor=H286888569#H286888569\">",
"      \"Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)\", section on 'Endometrial cancer in the young woman'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413495404\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18219271\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23747?source=see_link\">",
"      Patient information: Uterine cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18219289\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=see_link\">",
"      Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"      Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36983?source=see_link\">",
"      Endometrial carcinoma: Histopathology and pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22825?source=see_link\">",
"      Treatment of locally advanced, recurrent, or metastatic endometrial cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22584?source=see_link\">",
"      Type II endometrial carcinomas (eg, serous, clear cell, mucinous)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15257?source=see_link\">",
"      Treatment and prognosis of uterine leiomyosarcoma",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.org/index.asp\">",
"      file://www.nccn.org/index.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gynecologic Oncology Group",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gog.org/gynecologiccancerinformation.html\">",
"      www.gog.org/gynecologiccancerinformation.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?18/55/19314/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?18/55/19314?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19314/abstract/1\">",
"      American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19314/abstract/2\">",
"      Zerbe MJ, Bristow R, Grumbine FC, Montz FJ. Inability of preoperative computed tomography scans to accurately predict the extent of myometrial invasion and extracorporal spread in endometrial cancer. Gynecol Oncol 2000; 78:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19314/abstract/3\">",
"      Lee TS, Jung JY, Kim JW, et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma. Gynecol Oncol 2007; 104:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19314/abstract/4\">",
"      Barakat RR, Lev G, Hummer AJ, et al. Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gynecol Oncol 2007; 105:150.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f18_55_19314=[""].join("\n");
var outline_f18_55_19314=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           THE UTERUS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ENDOMETRIAL CANCER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           ENDOMETRIAL CANCER DIAGNOSIS AND STAGING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ENDOMETRIAL CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PREGNANCY AND ENDOMETRIAL CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\" title=\"figure 1\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f18_55_19315="Iodine: Pediatric drug information";
var content_f18_55_19315=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iodine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/19/10548?source=see_link\">",
"    see \"Iodine: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iodex&reg; [OTC];",
"     </li>",
"     <li>",
"      Iodoflex&trade; [OTC];",
"     </li>",
"     <li>",
"      Iodosorb&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/19/10548?source=see_link\">",
"      see \"Iodine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antiseptic for minor cuts, scrapes: Apply small amount to affected area 1-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cleaning wet ulcers and wounds (Iodosorb&reg;, Iodoflex&trade;): Apply to clean wound; maximum: 50 g/application and 150 g/week. Change dressing &sim;3 times/week; reduce applications as exudate decreases. Do not use for &gt;3 months; discontinue when wound is free of exudate.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dressing, topical [gel pad]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iodoflex&trade;: 0.9% (3s, 5s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iodosorb&reg;: 0.9% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iodex&reg;: 4.7% (30 g, 720 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tincture, topical [mild]: 2% (59 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tincture, topical [strong]: 7% (30 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tincture, swabstick, topical [mild]: 2% (50s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tincture",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply to affected areas; avoid tight bandages because iodine may cause burns on occluded skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Iodosorb&reg;: Apply 1/8\" to 1/4\" thickness to dry sterile gauze, then place prepared gauze onto clean wound. Change dressing when gel changes color from brown to yellow/gray (&sim;3 times/week). Remove with sterile water, saline, or wound cleanser; gently blot fluid from surface leaving wound slightly moist before reapplying gel.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2874883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used topically as an antiseptic in the management of minor, superficial skin wounds and has been used to disinfect the skin preoperatively",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F183695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Iodine may be confused with codeine, Iopidine&reg;, Lodine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F183694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reactions reported following topical application:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: TSH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Eczema, edema, irritation, pain, redness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Reactions reported more likely observed following large doses or chronic iodine intoxication; frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin rash, angioedema, urticaria, acne",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Metallic taste, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia, hemorrhage (mucosal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Swelling of eyelids",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Ioderma, lymph node enlargement",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodine preparations or any component; neonates; Hashimoto thyroiditis, history of Grave&rsquo;s disease, or nontoxic nodular goiter",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2874881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution in patients with renal dysfunction; since iodine may be absorbed systemically, thyroid function may need to be monitored when used chronically or over a large area.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be highly toxic if ingested; iodine may be absorbed systemically, especially when large wounds are treated or when used in neonates. Not for application to large areas of the body or for use with tight or air-excluding bandages. When used for self medication (OTC), do not use on deep wounds, puncture wounds, animal bites, or serious burns without consulting with healthcare provider. Notify healthcare provider if condition does not improve within 7 days. Iodosorb&reg; is for use as topical application to wet wounds only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2521600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An adequate amount of iodine intake is essential for thyroid function. Iodine crosses the placenta and requirements are increased during pregnancy. Iodine deficiency in pregnancy can lead to neurologic damage in the newborn; an extreme form, cretinism, is characterized by gross mental retardation, short stature, deaf mutism, and spasticity. Large amounts of iodine during pregnancy can cause fetal goiter or hyperthyroidism. Transient hypothyroidism in the newborn has also been reported following topical or vaginal use prior to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Free iodine oxidizes microbial protoplasm making it effective against bacteria, fungi, yeasts, protozoa, and viruses; complexes with amino groups in tissue compounds to form iodophors from which the iodine is slowly released causing a sustained action. Iodosorb&reg; and Iodoflex&trade; contain iodine in hydrophilic beads of cadexomer which allows a slow release of iodine into the wound.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2874884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Amount absorbed systemically depends upon the iodine concentration and skin characteristics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Degraded by amylases normally present in wound fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;90%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May stain skin and clothing; may experience transient pain within the first hour after application",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1059439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium thiosulfate inactivates iodine and is an effective chemical antidote for iodine poisoning; solutions of sodium thiosulfate may be used to remove iodine stains from skin and clothing",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13385 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.32.226.102-B08792FACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19315=[""].join("\n");
var outline_f18_55_19315=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183684\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059432\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059428\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183680\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183670\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059436\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874883\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059435\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183695\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183694\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059438\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874881\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059427\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299526\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221077\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521600\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059426\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874884\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059431\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059439\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13385\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13385|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/19/10548?source=related_link\">",
"      Iodine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_55_19316="Ziconotide: Patient drug information";
var content_f18_55_19316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ziconotide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/55/38773?source=see_link\">",
"     see \"Ziconotide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prialt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ziconotide may cause or make diseases of the mind worse. Hallucinations, psychoses, confusion, and memory loss have happened with use. If you think you have any of these health problems, call your doctor right away. Stop this drug if you have very bad signs of these health problems or signs that get worse. These problems are most often fixed after you stop the drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ziconotide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703814",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have psychosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Neck stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the spine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11343 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19316=[""].join("\n");
var outline_f18_55_19316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235295\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013370\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013372\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013371\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013376\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013377\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013379\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013374\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013375\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013380\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013381\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/55/38773?source=related_link\">",
"      Ziconotide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_55_19317="Budesonide (nasal): Drug information";
var content_f18_55_19317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Budesonide (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/59/8116?source=see_link\">",
"    see \"Budesonide (nasal): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/35/42547?source=see_link\">",
"    see \"Budesonide (nasal): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7998588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rhinocort Aqua&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7998589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mylan-Budesonide AQ;",
"     </li>",
"     <li>",
"      Rhinocort&reg; Aqua&reg;;",
"     </li>",
"     <li>",
"      Rhinocort&reg; Turbuhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7998592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Nasal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7998753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nasal polyps:",
"     </b>",
"     <i>",
"      Nasal inhalation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rhinocort&reg; Aqua&reg;: 256 mcg/day administered as a single 64 mcg spray in each nostril twice daily; maximum dose: 256 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rhinocort&reg; Turbuhaler&reg;:  100 mcg into each nostril twice daily; maximum: 400 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Rhinitis:",
"     </b>",
"     <i>",
"      Nasal inhalation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling",
"     </i>",
"     (Rhinocort&reg; Aqua&reg;): 64 mcg/day as a single 32 mcg spray in each nostril. Some patients who do not achieve adequate control may benefit from increased dosage. A reduced dosage may be effective after initial control is achieved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum dose: Children &lt;12 years: 128 mcg/day; Adults: 256 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rhinocort&reg; Aqua&reg;: Initial: 256 mcg/day administered as two 64 mcg sprays in each nostril once daily or a single 64 mcg spray in each nostril twice daily; Maintenance: Individualize, lowest effective dose (maximum dose: 256 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rhinocort&reg; Turbuhaler&reg;:  Initial: 200 mcg into each nostril once daily; Maintenance: Individualize, lowest effective dose (maximum: 400 mcg/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7998752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/35/42547?source=see_link\">",
"      see \"Budesonide (nasal): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nasal polyps:",
"     </b>",
"     <i>",
"      Nasal inhalation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Rhinitis:",
"     </b>",
"     <i>",
"      Nasal inhalation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling (Rhinocort&reg; Aqua&reg;): Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling (Rhinocort&reg; Aqua&reg;, Rhinocort&reg; Turbuhaler&reg;): Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7998754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7998755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Systemic availability of budesonide may be increased in patients with cirrhosis; monitor closely for signs and symptoms of hypercorticism; dosage reduction may be required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7998763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinocort Aqua&reg;: 32 mcg/inhalation (8.6 g) [120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F7998764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for nasal inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinocort&reg; Turbuhaler&reg;: 100 mcg/inhalation [delivers 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinocort&reg; Aqua&reg;: 64 mcg/inhalation [120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7998590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7998756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for nasal inhalation: Rhinocort&reg; Turbuhaler&reg; [CAN, not available in the U.S.]: Hold inhaler in upright position and turn grey grip as far as it will go in one direction and then back to original position. Clicking sound means inhaler is loaded with dose and ready for use. Place nasal adapter into nostril and ensure firm fit. Cover opposite nostril with finger and inhale (sniff) quickly and forcefully. Do not exhale through inhaler. When a red mark appears in the dose indicator window, 20 doses are left. When the red mark reaches the bottom of the window, the inhaler should be discarded",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension for nasal inhalation: Shake gently before use. Prime before first use; discard after 120 sprays.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7998630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Management of symptoms of seasonal or perennial rhinitis",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Prevention and treatment of nasal polyps",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14225121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis (ABRS) (Chow, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7998638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (8%), pharyngitis (4%), bronchospasm (2%), coughing (2%), nasal irritation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Although reported at higher rates with systemic administration, symptoms of HPA axis suppression and/or hypercorticism may occur rarely (&lt;1%) following administration via methods which result in lower exposures (nasal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, (Limited to important or life-threatening): Anosmia, growth suppression, hypersensitivity reactions (immediate and delayed [includes rash, contact dermatitis, angioedema, bronchospasm]), nasal septum perforation, pharyngeal disorders (irritation, throat pain, itchy throat)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7998634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to budesonide or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Pulmonary tuberculosis (active or quiescent), untreated respiratory infection (bacterial, fungal, or viral); use in patients &lt;6 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7998635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided. Close observation is required in patients with latent tuberculosis and/or TB reactivity restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Local nasal infections: Localized",
"     <i>",
"      Candida albicans",
"     </i>",
"     infections of the nose and/or pharynx may occur (rarely).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled and intranasal corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Budesonide (Nasal). Management: Concurrent use of telaprevir with inhaled budesonide is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7998631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7998632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Studies of pregnant women using intranasal budesonide have not demonstrated an increased risk of abnormalities. Intranasal corticosteroids may be used in the treatment of rhinitis during pregnancy; budesonide is preferred (Wallace,  2008)",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8112610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8112611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following use of the powder for oral inhalation, ~0.3% to 1% of the maternal dose was found in breast milk. The maximum concentration appeared within 45 minutes of dosing. Plasma budesonide levels obtained from infants ~90 minutes after breast-feeding (~140 minutes after maternal dose) were below the limit of quantification. Milk concentrations following the use of the nasal inhaler are expected to be similar. The use of inhaled corticosteroids is not considered a contraindication to breast feeding (NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7998766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Rhinocort Aqua Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32 mcg/ACT (8.6 g): $151.55",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7998758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor growth in pediatric patients",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Allercort (TW);",
"     </li>",
"     <li>",
"      Besonin Aqua (MY, TH);",
"     </li>",
"     <li>",
"      Budamax (AU);",
"     </li>",
"     <li>",
"      Budecort Nasal (PH);",
"     </li>",
"     <li>",
"      Budeflam (ZA);",
"     </li>",
"     <li>",
"      Budena (HK);",
"     </li>",
"     <li>",
"      Budenase AQ (HK);",
"     </li>",
"     <li>",
"      Budeson Aqua (TW);",
"     </li>",
"     <li>",
"      Butacort (NZ);",
"     </li>",
"     <li>",
"      Eltair (NZ, SG);",
"     </li>",
"     <li>",
"      Esonide (SG);",
"     </li>",
"     <li>",
"      Nastizol Hidrospray (PY);",
"     </li>",
"     <li>",
"      Pulmicort Nasal (KP, PL, TW);",
"     </li>",
"     <li>",
"      Rhinocort (AU, BB, BE, BM, BS, CH, CL, CN, CO, CR, DK, DO, EE, FI, FR, GB, GT, HK, HN, ID, IE, IN, IT, JM, NI, NL, NO, NZ, PA, PE, PL, PR, SE, SV, TH, TR, TT, VE);",
"     </li>",
"     <li>",
"      Rhinocort Hayfever (AU);",
"     </li>",
"     <li>",
"      Timat (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7998662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation. Has potent glucocorticoid activity and weak mineralocorticoid activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7998664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Rhinocort&reg; Aqua&reg;: ~10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Rhinocort&reg; Aqua&reg;: ~2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 2.2-3.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 to two metabolites: 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide; minor activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Limited by high first-pass effect; Nasal: 34%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Nasal: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60%) and feces as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/55/19317/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/55/19317/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/55/19317/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace DV, Dykewicz MS, Bernstein DI, et al, &ldquo;The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2008, 122(2 Suppl):1-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/55/19317/abstract-text/18662584/pubmed\" id=\"18662584\" target=\"_blank\">",
"        18662584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9034 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19317=[""].join("\n");
var outline_f18_55_19317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998588\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998589\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998592\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998753\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998752\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998754\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682319\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998755\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998763\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998764\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998590\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998756\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998630\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225121\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998638\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998634\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998635\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082584\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082585\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998631\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998632\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8112610\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8112611\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998766\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998758\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961960\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998662\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998664\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9034|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/59/8116?source=related_link\">",
"      Budesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/35/42547?source=related_link\">",
"      Budesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10873?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/45/25303?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21064?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_55_19318="Kasai hepatoportoenterostomy";
var content_f18_55_19318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Kasai hepatoportoenterostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 696px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Kasai hepatoportoenterostomy the bile ducts are excised and a limb of jejunum is anastamosed to the liver. The distal duodenum is anastomosed to the jejunal limb to create a Roux-en-Y configuration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19318=[""].join("\n");
var outline_f18_55_19318=null;
var title_f18_55_19319="Skin biopsy lupus profundus I";
var content_f18_55_19319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80683%7ERHEUM%2F59536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80683%7ERHEUM%2F59536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus profundus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy of a patient with lupus profundus showing expansion of the interstices of the fat lobule with disintegrating leukocytes and fibrin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus profundus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histiocytes within the fat lobule contain engulfed nuclear debris producing cells with a morphology reminiscent of an LE cell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19319=[""].join("\n");
var outline_f18_55_19319=null;
var title_f18_55_19320="Oral habits and orofacial development in children";
var content_f18_55_19320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oral habits and orofacial development in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/55/19320/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19320/contributors\">",
"     Arthur J Nowak, DMD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19320/contributors\">",
"     John J Warren, DDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/55/19320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19320/contributors\">",
"     Ann Griffen, DDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/55/19320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19320/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/55/19320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral habits that are acquired during infancy (eg, nonnutritive sucking) can have adverse health consequences, such as early cessation of breastfeeding or increased risk of otitis media. The identification of such habits and assessment of immediate and long-term effects on the teeth and orofacial development should be made as early as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. After infancy, persistent oral habits have little effect on health but can affect facial growth, oral function, the occlusal relationship, and facial esthetics [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/3\">",
"     3",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The short- and long-term effects of oral habits are reviewed here. Preventive dental care and counseling for infants and young children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33192?source=see_link\">",
"     \"Preventive dental care and counseling for infants and young children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONNUTRITIVE SUCKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonnutritive sucking behavior (eg, sucking on a pacifier, thumb, or fingers) is a normal part of early development that may become a learned habit. It is a self-soothing behavior that occurs in 70 to 90 percent of infants in various populations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. The frequency of sucking on digits or pacifiers decreases with increasing age; by the age of four to five years, nonnutritive sucking usually is replaced by other coping mechanisms, and the prevalence decreases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who use a pacifier are less likely to suck on their thumb or fingers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Compared with pacifier sucking, digit sucking is more likely to persist into the fourth or fifth year of life, when it may become problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. If it persists into the period of permanent tooth eruption, nonnutritive sucking may contribute to the development of malocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/14\">",
"     14",
"    </a>",
"    ]. Pacifier use does not appear to be related to an increased risk of development of early childhood caries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15700700\">",
"    <span class=\"h2\">",
"     Overview of effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonnutritive sucking habits may be associated with increased prevalence of malocclusion in the primary dentition and mixed dentition, and increased risk of trauma to the upper front teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the dental effects of nonnutritive sucking, pacifier use has been associated with numerous other health effects, including increased risk of development of otitis media, early cessation of breastfeeding, and possible decreased risk of sudden infant death syndrome (SIDS). These effects are less clearly associated with digit sucking. A cause-and-effect relationship for these associations has not been established, and in some situations reverse causality may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dental effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between digit sucking and abnormalities in the primary dentition was reported as early as the 1870s [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. It is described in several retrospective studies, many of which used questionnaires to assess sucking behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/16,17,23-28\">",
"     16,17,23-28",
"    </a>",
"    ]. The association is consistent, although its strength varies depending upon the study. The risk of malocclusion increases directly with frequency, duration, and intensity of sucking habit and is not eliminated by the use of \"orthodontic\" pacifiers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/3,17,26\">",
"     3,17,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following types of malocclusion in the primary dentition are associated with sucking habits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/3,29\">",
"     3,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open bite (the upper and lower anterior teeth do not overlap)",
"     </li>",
"     <li>",
"      Posterior crossbite (the upper posterior teeth bite inside the lower posterior teeth on one or both sides)",
"     </li>",
"     <li>",
"      Excessive overjet (excessive horizontal overlap of the upper relative to the lower front teeth); in children with digit habits, it may be exacerbated by lower incisors that are positioned toward the tongue (lingually positioned)",
"     </li>",
"     <li>",
"      Class II relationship (the upper jaw protrudes too far in front of the lower jaw)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few studies have evaluated whether habit-related malocclusion of the primary dentition persists into the permanent dentition. In one longitudinal study of 116 Australian children two to eight years of age, persistent finger sucking was related to increased overjet and a proportion of Class II malocclusions; dental arch width was not affected [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. &nbsp;In contrast, pacifier use was associated with decreased arch width that typically resolved within two to three years after pacifier use was discontinued. Increased prevalence of posterior crossbite among children with nonnutritive sucking habits was not noted in this study.",
"   </p>",
"   <p>",
"    A cross-sectional study of 320 nine-year-old children evaluated the relationship between various patterns of digit and pacifier sucking and facial growth and occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/32\">",
"     32",
"    </a>",
"    ]. Finger-sucking was associated with greater overjet, decreased maxillary arch width, and increased maxillary arch length. The effects of pacifier use were more pronounced when pacifier use was continued beyond the age of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/32\">",
"     32",
"    </a>",
"    ]. The permanent dentition of a subset of the cohort was examined when they reached 16 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/33\">",
"     33",
"    </a>",
"    ]. Skeletal changes, including anterior rotation of the nasal and mandibular planes, were found more commonly among those with a previous sucking habit than in those without. In addition, Class II malocclusions and traumatic injuries to the maxillary anterior teeth were found more commonly among those with a history of finger sucking than those who used a pacifier or did not have a sucking habit.",
"   </p>",
"   <p>",
"    In a study of children undergoing orthodontic treatment for excessive overjet, there was no correlation between severity of overjet and the prevalence of trauma to the incisors (approximately 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/34\">",
"     34",
"    </a>",
"    ]. Children with a history of trauma were likely to report additional trauma. Most of the injuries were mild and involved the permanent central incisors.",
"   </p>",
"   <p>",
"    Another study evaluated the relationship between sucking habits and malocclusion and swallowing habits of 10- to 11-year-old children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/35\">",
"     35",
"    </a>",
"    ]. &nbsp;Among children with a history of a sucking habit, persistence of a tongue thrust swallowing pattern was found more commonly; this swallowing pattern was associated with Class II malocclusion, extreme maxillary overjet, and open bite. However, the tongue-thrust pattern did not account completely for malocclusion because there was an increased frequency of malocclusion independent of the swallowing pattern.",
"   </p>",
"   <p>",
"    A study of 444 eight- and nine-year-old children who had extensive longitudinal nonnutritive sucking data collected periodically from birth found that prolonged pacifier habits (to 24 to 47 months of age) were associated with increased occurrence of anterior open bite and Class II malocclusion in the early mixed dentition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/18\">",
"     18",
"    </a>",
"    ]. Prolonged digit habits were associated with anterior open bite, although any habit (digit",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pacifier) was associated with posterior crossbite [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between pacifier use and acute otitis media (AOM) has been reported in one meta-analysis and several prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The meta analysis evaluating the risk factors for AOM found pacifier use was associated with increased risk of development of otitis media (pooled relative risk 1.24, 95% CI, 1.06-1.46) based upon two studies involving 4110 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/37,39,40\">",
"     37,39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association of digit sucking and otitis media is less clear; it was not found in either of the studies described above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], but it has been described in others [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between pacifier use and early cessation of breastfeeding has been documented in several longitudinal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/42-50\">",
"     42-50",
"    </a>",
"    ]. The association remains even after controlling for potential confounding variables including age, sex, birth weight, maternal education, and family income. In these studies, early cessation of breastfeeding is two to three times more likely to occur among pacifier users than non-users. Pacifiers also have been associated with shorter duration of breastfeeding at each feeding event and fewer feeding events per day [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cause-and-effect relationship between pacifier use and early cessation of breastfeeding has not been established, and it may be that pacifier use is a marker for breastfeeding problems or reduced motivation to breastfeed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/51\">",
"     51",
"    </a>",
"    ]. An alternative explanation is that such pacifier use contributes to a faulty sucking technique, which in turn leads to breastfeeding problems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/42,52,53\">",
"     42,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between digit sucking and early cessation of breastfeeding is reported in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/50\">",
"     50",
"    </a>",
"    ] but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     SIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between pacifier use and decreased incidence of sudden infant death syndrome (SIDS) has been reported in case-control studies (odds ratio 0.38 to 0.44 in various studies) [54-58]. Although a cause-and-effect relationship has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], one meta-analysis found that pacifiers given for sleep had \"dramatic beneficial results\" in preventing SIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/56\">",
"     56",
"    </a>",
"    ]. Based on what they called \"compelling\" evidence, the American Academy of Pediatrics recommended in a November 2005 policy statement that pacifiers be offered to infants at nap- and bed-time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Miscellaneous effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digit sucking is associated with an increased risk of development of chronic infections (eg, paronychia)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    potential orthopedic problems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37846?source=see_link\">",
"     \"Paronychia and ingrown toenails\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pacifier use is associated with increased frequency of oral yeast infections and levels of Candida organisms in the mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/59-61\">",
"     59-61",
"    </a>",
"    ] and has been identified as a risk factor for lead poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, pacifier use has been associated with increased parent-reported symptoms (wheezing, earache, vomiting, fever, diarrhea, and colic) in four- to six-month-old infants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/63\">",
"     63",
"    </a>",
"    ]. &nbsp;However, in this questionnaire survey, the cause-and-effect relationship was not established, and the pacifier may have been used as a means of comfort after the illness was established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15700707\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15706307\">",
"    <span class=\"h3\">",
"     Pacifier use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for pacifier use must balance the potential risks and benefits. The American Academy of Pediatrics suggests that for breastfed infants the introduction of a pacifier be delayed until breast feeding is well established (one month of age), but that thereafter pacifiers be offered at sleep to reduce the risk of SIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15700715\">",
"    <span class=\"h3\">",
"     Breaking the habit",
"    </span>",
"    &nbsp;&mdash;&nbsp;To minimize dental effects, we recommend intervention to address sucking habits by three years of age. Consultation with the child's dental health provider should be obtained.",
"   </p>",
"   <p>",
"    The level of intervention for nonnutritive sucking habits depends upon the severity of the problem (eg, frequency, intensity, and duration of the habit) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/64\">",
"     64",
"    </a>",
"    ]. As a general rule, the habit may be more difficult to break if it is \"meaningful\" (maintained by some underlying psychologic disturbance), conscious, and generalized across multiple settings and if the child is older, female, and not willing to cooperate in cessation efforts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strategies may include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinuation of parental comments about thumb sucking if parental attention appears to have reinforced the behavior",
"     </li>",
"     <li>",
"      Management of sources of stress and anxiety in the child's life",
"     </li>",
"     <li>",
"      A program consisting of positive reinforcement for avoidance of digit sucking (eg, a sticker chart) and the application of an aversive tasting substance to the digit",
"     </li>",
"     <li>",
"      Intraoral dental appliances that serve as a reminder not to suck",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      that interfere with the seal that is necessary for sucking are effective interventions when necessary",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MOUTH-BREATHING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15700722\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic mouth-breathing can be caused by chronic nasal",
"    <span class=\"nowrap\">",
"     obstruction/congestion",
"    </span>",
"    (eg, from allergies or asthma), adenoidal hypertrophy, or anatomic abnormalities (eg, cleft palate), or it may be a learned habit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. Chronic mouth-breathing is reported to be associated with a characteristic pattern of facial growth; however, the association is disputed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15700729\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of chronic mouth-breathing among children depends upon the method of assessment and the age of the child [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. It ranges from 9 percent of four-year-olds (based on parental report) to 40 percent of first-graders (based upon a 15-minute observation period), although these methods of ascertainment have not been correlated with clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/69,70,73-75\">",
"     69,70,73-75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15700736\">",
"    <span class=\"h2\">",
"     Orofacial effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several, but not all, studies suggest that chronic mouth-breathing produces long, narrow faces and that treatment of nasal obstruction results in improved facial morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/69,76-78\">",
"     69,76-78",
"    </a>",
"    ]. These studies are limited by the lack of a consistent, clinically relevant definition of chronic mouth-breathing, leading to possible misclassification of subjects in at least some studies. Nonetheless, the evidence seems to support an association between nasal obstruction and malocclusion and undesirable facial morphology. Studies in animals support the association [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary orofacial effects of chronic mouth-breathing include narrowing of the maxillary arch, over-eruption of the permanent molars, and downward and posterior rotation of the mandible. These effects are mediated through the altered tongue position and the open-mouth posture. It is not known what proportion of time must be spent in mouth-breathing to be clinically relevant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Narrow upper arch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maxillary arch width is reduced (resulting in posterior crossbite) in children who are chronic mouth-breathers, compared with age-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sex-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/72,80-84\">",
"     72,80-84",
"    </a>",
"    ]. The narrow maxillary arch in chronic mouth-breathers is related to the altered position of the tongue in oral compared with nasal breathing. In nasal breathing, the tongue rests against the palate where it exerts lateral pressure and plays an important role in the widening of the maxillary arch. In contrast, in mouth-breathing, the tongue rests lower in the oral cavity and thus exerts less lateral pressure on the maxillary arch [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mandibular rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent teeth typically continue to erupt until they make contact with teeth or tissue in the opposing arch. Because this contact is missing in chronic mouth-breathers, over-eruption of the permanent molars may result. Over-eruption of the permanent molars can lead to downward and posterior rotation of the mandible [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/65,66\">",
"     65,66",
"    </a>",
"    ], resulting in increased height of the lower face and retrusion of the mandible [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/72,75,80-83,86\">",
"     72,75,80-83,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between mandibular rotation and nasal obstruction is supported by numerous studies in which treatment of nasal obstruction (eg, adenoidectomy, aggressive treatment of asthma or nasal allergies) led to improved mandibular position [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the mandibular morphology of 26 children who were five years status postadenoidectomy for nasal obstruction was compared with that of age- and sex-matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/76\">",
"       76",
"      </a>",
"      ]. Surgery resulted in improved facial height and less retrusive mandibles compared with preoperative morphology. However, the morphology of the adenoidectomy group remained different from that of a control group with no history of mouth-breathing or nasal airway obstruction.",
"     </li>",
"     <li>",
"      In another study, pre- and postoperative dental casts and mandibular radiographs of 22 children who underwent tonsillectomy for sleep apnea were compared with those of children without upper airway obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/77\">",
"       77",
"      </a>",
"      ]. Two years after surgery, anterior open bites and posterior crossbites had resolved in 16 of 19 children; the best results were obtained in children who underwent surgery before reaching the age of six years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120458254\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend early and aggressive treatment, including referral to an otolaryngologist if necessary, for any respiratory or anatomic problem that predisposes a young child to a mouth-breathing pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     BRUXISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bruxism, the habitual grinding of teeth, usually occurs during sleep, but it also can occur as an unconscious habit during the waking hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/87\">",
"     87",
"    </a>",
"    ]. It is reported to occur in 15 to 24 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. The frequency of bruxism peaks between 7 and 10 years of age, and then it decreases; it rarely persists through adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/6,87,90\">",
"     6,87,90",
"    </a>",
"    ]. In children, although bruxism is sometimes linked to stress [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/91\">",
"     91",
"    </a>",
"    ] or parasomnias [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/92\">",
"     92",
"    </a>",
"    ], it is typically a self-limited problem and rarely requires intervention. In contrast, bruxism in adults can cause severe damage to the teeth and is associated with muscular headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19320/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15700743\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonnutritive sucking (eg, sucking on a pacifier, thumb, or fingers) is a self-soothing behavior that is normal in early development but may become a learned habit. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nonnutritive sucking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonnutritive sucking is associated with increased prevalence of malocclusion in the primary and mixed dentition and increased risk of trauma to the upper front teeth. The prevalence of malocclusion increases with increased duration of the sucking habit. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dental effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pacifier use is associated with an increased risk of otitis media, early cessation of breastfeeding, and decreased risk of sudden infant death syndrome (SIDS). However, cause-and-effect relationships for these associations have not been established. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Otitis media'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Breastfeeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'SIDS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To minimize the dental effects of nonnutritive sucking, we recommend intervention to address sucking habits by three years of age. The level of intervention depends upon the severity of the problem. (See",
"      <a class=\"local\" href=\"#H15700715\">",
"       'Breaking the habit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic mouth-breathing can be caused by chronic nasal",
"      <span class=\"nowrap\">",
"       obstruction/congestion,",
"      </span>",
"      adenoidal hypertrophy, or anatomic abnormalities, or it may be a learned habit. (See",
"      <a class=\"local\" href=\"#H15700722\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic mouth breathing appears to be associated with orofacial effects, including narrowing of the maxillary arch, over-eruption of the permanent molars, and downward and posterior rotation of the mandible. It is not known what proportion of time must be spent in mouth-breathing to be clinically relevant. (See",
"      <a class=\"local\" href=\"#H15700736\">",
"       'Orofacial effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bruxism is the habitual grinding of teeth, usually during sleep. The frequency of bruxism peaks between 7 and 10 years of age and then declines. In children, bruxism is typically a self-limited problem and rarely requires intervention. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Bruxism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/1\">",
"      Johnson ED, Larson BE. Thumb-sucking: literature review. ASDC J Dent Child 1993; 60:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/2\">",
"      American Academy on Pediatric Dentistry Clinical Affairs Committee-Developing Dentition Subcommittee, American Academy on Pediatric Dentistry Council on Clinical Affairs. Guideline on management of the developing dentition and occlusion in pediatric dentistry. Pediatr Dent 2008; 30:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/3\">",
"      Josell SD. Habits affecting dental and maxillofacial growth and development. Dent Clin North Am 1995; 39:851.",
"     </a>",
"    </li>",
"    <li>",
"     Augustyn M, Frank DA, Zuckerman BS. Infancy and toddler years. In: Developmental-Behavioral Pediatrics, 4th, Carey WB, Crocker AC, Coleman WL, et al (Eds), Saunders Elsevier, Philadelphia 2009. p.24.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/5\">",
"      BRAZELTON TB. Crying in infancy. Pediatrics 1962; 29:579.",
"     </a>",
"    </li>",
"    <li>",
"     Blum N.. Repetitive behaviors and tics. In: Developmental-Behavioral Pediatrics, 4th, Carey WB, Crocker AC, Coleman WL, et al (Eds), Saunders Elsevier, Philadelphia 2009. p.629.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/7\">",
"      Field T, Goldson E. Pacifying effects of nonnutritive sucking on term and preterm neonates during heelstick procedures. Pediatrics 1984; 74:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/8\">",
"      Nowak AJ, Warren JJ. Infant oral health and oral habits. Pediatr Clin North Am 2000; 47:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/9\">",
"      Larsson E. The prevalence and aetiology of prolonged dummy and finger-sucking habits. Eur J Orthod 1985; 7:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/10\">",
"      Zadik D, Stern N, Litner M. Thumb- and pacifier-sucking habits. Am J Orthod 1977; 71:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/11\">",
"      K&ouml;hler L, Holst K. Malocclusion and sucking habits of four-year-old children. Acta Paediatr Scand 1973; 62:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/12\">",
"      Larsson E. Treatment of children with a prolonged dummy or finger-sucking habit. Eur J Orthod 1988; 10:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/13\">",
"      Warren JJ, Bishara SE. Duration of nutritive and nonnutritive sucking behaviors and their effects on the dental arches in the primary dentition. Am J Orthod Dentofacial Orthop 2002; 121:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/14\">",
"      Friman PC, Schmitt BD. Thumb sucking: pediatricians' guidelines. Clin Pediatr (Phila) 1989; 28:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/15\">",
"      Peressini S. Pacifier use and early childhood caries: an evidence-based study of the literature. J Can Dent Assoc 2003; 69:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/16\">",
"      Lindner A, Mod&eacute;er T. Relation between sucking habits and dental characteristics in preschoolchildren with unilateral cross-bite. Scand J Dent Res 1989; 97:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/17\">",
"      Adair SM, Milano M, Lorenzo I, Russell C. Effects of current and former pacifier use on the dentition of 24- to 59-month-old children. Pediatr Dent 1995; 17:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/18\">",
"      Warren JJ, Slayton RL, Bishara SE, et al. Effects of nonnutritive sucking habits on occlusal characteristics in the mixed dentition. Pediatr Dent 2005; 27:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/19\">",
"      Ravn JJ. Sucking habits and occlusion in 3-year-old children. Scand J Dent Res 1976; 84:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/20\">",
"      Engelberts AC, L'Hoir MP. Pacifier use and SIDS. Arch Dis Child 2000; 82:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/21\">",
"      Campbell M. Fruitless sucking. Brit J Dent Sci 1870; 13:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/22\">",
"      Chandler TH. Thumb-sucking. Dent Cosmos 1878; 20:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/23\">",
"      Helle A, Haavikko K. Prevalence of earlier sucking habits revealed by anamnestic data and their consequences for occlusion at the age of eleven. Proc Finn Dent Soc 1974; 70:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/24\">",
"      Ogaard B, Larsson E, Lindsten R. The effect of sucking habits, cohort, sex, intercanine arch widths, and breast or bottle feeding on posterior crossbite in Norwegian and Swedish 3-year-old children. Am J Orthod Dentofacial Orthop 1994; 106:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/25\">",
"      Infante PF. An epidemiologic study of finger habits in preschool children, as related to malocclusion, socioeconomic status, race, sex, and size of community. ASDC J Dent Child 1976; 43:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/26\">",
"      Adair SM, Milano M, Dushku JC. Evaluation of the effects of orthodontic pacifiers on the primary dentitions of 24- to 59-month-old children: preliminary study. Pediatr Dent 1992; 14:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/27\">",
"      Katz CR, Rosenblatt A, Gondim PP. Nonnutritive sucking habits in Brazilian children: effects on deciduous dentition and relationship with facial morphology. Am J Orthod Dentofacial Orthop 2004; 126:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/28\">",
"      Viggiano D, Fasano D, Monaco G, Strohmenger L. Breast feeding, bottle feeding, and non-nutritive sucking; effects on occlusion in deciduous dentition. Arch Dis Child 2004; 89:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/29\">",
"      Moore MB, McDonald JP. A cephalometric evaluation of patients presenting with persistent digit sucking habits. Br J Orthod 1997; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/30\">",
"      Bowden BD. A longitudinal study of the effects of digit- and dummy-sucking. Am J Orthod 1966; 52:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/31\">",
"      Bowden BD. The effects of digital and dummy sucking on arch widths, overbite, and overjet: a longitudinal study. Aust Dent J 1966; 11:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/32\">",
"      Larrson E. Dummy- and finger-sucking habits with special attention to their significance for facial growth and occlusion. Swed Dent J 1972; 65:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/33\">",
"      Larsson E. Dummy- and finger-sucking habits with special attention to their significance for facial growth and occlusion. 7. The effect of earlier dummy- and finger-sucking habit in 16-year-old children compared with children without earlier sucking habit. Swed Dent J 1978; 2:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/34\">",
"      Chen DR, McGorray SP, Dolce C, Wheeler TT. Effect of early Class II treatment on the incidence of incisor trauma. Am J Orthod Dentofacial Orthop 2011; 140:e155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/35\">",
"      Melsen B, Stensgaard K, Pedersen J. Sucking habits and their influence on swallowing pattern and prevalence of malocclusion. Eur J Orthod 1979; 1:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/36\">",
"      Niemel&auml; M, Uhari M, M&ouml;tt&ouml;nen M. A pacifier increases the risk of recurrent acute otitis media in children in day care centers. Pediatrics 1995; 96:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/37\">",
"      Uhari M, M&auml;ntysaari K, Niemel&auml; M. A meta-analytic review of the risk factors for acute otitis media. Clin Infect Dis 1996; 22:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/38\">",
"      Warren JJ, Levy SM, Kirchner HL, et al. Pacifier use and the occurrence of otitis media in the first year of life. Pediatr Dent 2001; 23:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/39\">",
"      Larsson E. Dummy- and finger-sucking habits in 4-year-olds. Sven Tandlak Tidskr 1975; 68:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/40\">",
"      Niemel&auml; M, Uhari M, Hannuksela A. Pacifiers and dental structure as risk factors for otitis media. Int J Pediatr Otorhinolaryngol 1994; 29:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/41\">",
"      Jackson JM, Mourino AP. Pacifier use and otitis media in infants twelve months of age or younger. Pediatr Dent 1999; 21:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/42\">",
"      Righard L, Alade MO. Breastfeeding and the use of pacifiers. Birth 1997; 24:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/43\">",
"      Victora CG, Tomasi E, Olinto MT, Barros FC. Use of pacifiers and breastfeeding duration. Lancet 1993; 341:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/44\">",
"      Ford RP, Mitchell EA, Scragg R, et al. Factors adversely associated with breast feeding in New Zealand. J Paediatr Child Health 1994; 30:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/45\">",
"      Clements MS, Mitchell EA, Wright SP, et al. Influences on breastfeeding in southeast England. Acta Paediatr 1997; 86:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/46\">",
"      Barros FC, Victora CG, Semer TC, et al. Use of pacifiers is associated with decreased breast-feeding duration. Pediatrics 1995; 95:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/47\">",
"      Victora CG, Behague DP, Barros FC, et al. Pacifier use and short breastfeeding duration: cause, consequence, or coincidence? Pediatrics 1997; 99:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/48\">",
"      Howard CR, Howard FM, Lanphear B, et al. The effects of early pacifier use on breastfeeding duration. Pediatrics 1999; 103:E33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/49\">",
"      Aarts C, H&ouml;rnell A, Kylberg E, et al. Breastfeeding patterns in relation to thumb sucking and pacifier use. Pediatrics 1999; 104:e50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/50\">",
"      Levy SM, Slager SL, Warren JJ, et al. Associations of pacifier use, digit sucking, and child care attendance with cessation of breastfeeding. J Fam Pract 2002; 51:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/51\">",
"      Kramer MS, Barr RG, Dagenais S, et al. Pacifier use, early weaning, and cry/fuss behavior: a randomized controlled trial. JAMA 2001; 286:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/52\">",
"      Righard L, Alade MO. Sucking technique and its effect on success of breastfeeding. Birth 1992; 19:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/53\">",
"      Righard L. Are breastfeeding problems related to incorrect breastfeeding technique and the use of pacifiers and bottles? Birth 1998; 25:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/54\">",
"      Zotter H, Kerbl R, Kurz R, M&uuml;ller W. Pacifier use and sudden infant death syndrome: should health professionals recommend pacifier use based on present knowledge? Wien Klin Wochenschr 2002; 114:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/55\">",
"      McGarvey C, McDonnell M, Chong A, et al. Factors relating to the infant's last sleep environment in sudden infant death syndrome in the Republic of Ireland. Arch Dis Child 2003; 88:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/56\">",
"      Hauck FR, Omojokun OO, Siadaty MS. Do pacifiers reduce the risk of sudden infant death syndrome? A meta-analysis. Pediatrics 2005; 116:e716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/57\">",
"      American Academy of Pediatrics Task Force on Sudden Infant Death Syndrome. The changing concept of sudden infant death syndrome: diagnostic coding shifts, controversies regarding the sleeping environment, and new variables to consider in reducing risk. Pediatrics 2005; 116:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/58\">",
"      Rayan GM, Turner WT. Hand complications in children from digital sucking. J Hand Surg Am 1989; 14:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/59\">",
"      Ollila P, Niemel&auml; M, Uhari M, Larmas M. Prolonged pacifier-sucking and use of a nursing bottle at night: possible risk factors for dental caries in children. Acta Odontol Scand 1998; 56:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/60\">",
"      Mattos-Graner RO, de Moraes AB, Rontani RM, Birman EG. Relation of oral yeast infection in Brazilian infants and use of a pacifier. ASDC J Dent Child 2001; 68:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/61\">",
"      Hannula J, Saarela M, Jousimies-Somer H, et al. Age-related acquisition of oral and nasopharyngeal yeast species and stability of colonization in young children. Oral Microbiol Immunol 1999; 14:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/62\">",
"      Dalton MA, Sargent JD, Stukel TA. Utility of a risk assessment questionnaire in identifying children with lead exposure. Arch Pediatr Adolesc Med 1996; 150:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/63\">",
"      North K, Fleming P, Golding J. Pacifier use and morbidity in the first six months of life. Pediatrics 1999; 103:E34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/64\">",
"      Johnson ED, Larson BE. Thumb-sucking: classification and treatment. ASDC J Dent Child 1993; 60:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/65\">",
"      Strnad J. The cause and effect of mouth-breathing as related to malocclusion. Rhinology 1978; 16:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/66\">",
"      Principato JJ. Upper airway obstruction and craniofacial morphology. Otolaryngol Head Neck Surg 1991; 104:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/67\">",
"      Hairfield WM, Warren DW, Seaton DL. Prevalence of mouthbreathing in cleft lip and palate. Cleft Palate J 1988; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/68\">",
"      Warren DW, Hairfield WM, Seaton D, et al. The relationship between nasal airway size and nasal-oral breathing. Am J Orthod Dentofacial Orthop 1988; 93:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/69\">",
"      Kluemper GT, Vig PS, Vig KW. Nasorespiratory characteristics and craniofacial morphology. Eur J Orthod 1995; 17:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/70\">",
"      Parker LP, Crysdale WS, Cole P, Woodside D. Rhinomanometry in children. Int J Pediatr Otorhinolaryngol 1989; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/71\">",
"      Warren DW, Hairfield WM, Dalston ET. Effect of age on nasal cross-sectional area and respiratory mode in children. Laryngoscope 1990; 100:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/72\">",
"      Gross AM, Kellum GD, Franz D, et al. A longitudinal evaluation of open mouth posture and maxillary arch width in children. Angle Orthod 1994; 64:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/73\">",
"      Gurley WH, Vig PS. A technique for the simultaneous measurement of nasal and oral respiration. Am J Orthod 1982; 82:33.",
"     </a>",
"    </li>",
"    <li>",
"     Proffit WR. The etiology and development of orthodontic problems. In: Contemporary Orthodontics, Proffit WR, Fields HW (Eds), Mosby, St. Louis 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/75\">",
"      Gross AM, Kellum GD, Morris T, et al. Rhinometry and open-mouth posture in young children. Am J Orthod Dentofacial Orthop 1993; 103:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/76\">",
"      Kerr WJ, McWilliam JS, Linder-Aronson S. Mandibular form and position related to changed mode of breathing--a five-year longitudinal study. Angle Orthod 1989; 59:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/77\">",
"      Hultcrantz E, Larson M, Hellquist R, et al. The influence of tonsillar obstruction and tonsillectomy on facial growth and dental arch morphology. Int J Pediatr Otorhinolaryngol 1991; 22:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/78\">",
"      H&ouml;jensgaard E, Wenzel A. Dentoalveolar morphology in children with asthma and perennial rhinitis. Eur J Orthod 1987; 9:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/79\">",
"      Ousterhout DK, Vargervik K, Miller AJ. Nasal airway function as it relates to the timing of mid and lower facial osteotomies. Ann Plast Surg 1983; 11:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/80\">",
"      Bresolin D, Shapiro GG, Shapiro PA, et al. Facial characteristics of children who breathe through the mouth. Pediatrics 1984; 73:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/81\">",
"      Bresolin D, Shapiro PA, Shapiro GG, et al. Mouth breathing in allergic children: its relationship to dentofacial development. Am J Orthod 1983; 83:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/82\">",
"      Gross AM, Kellum GD, Michas C, et al. Open-mouth posture and maxillary arch width in young children: a three-year evaluation. Am J Orthod Dentofacial Orthop 1994; 106:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/83\">",
"      Venetikidou A. Incidence of malocclusion in asthmatic children. J Clin Pediatr Dent 1993; 17:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/84\">",
"      Oulis CJ, Vadiakas GP, Ekonomides J, Dratsa J. The effect of hypertrophic adenoids and tonsils on the development of posterior crossbite and oral habits. J Clin Pediatr Dent 1994; 18:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/85\">",
"      Adamidis IP, Spyropoulos MN. The effects of lymphadenoid hypertrophy on the position of the tongue, the mandible and the hyoid bone. Eur J Orthod 1983; 5:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/86\">",
"      Trask GM, Shapiro GG, Shapiro PA. The effects of perennial allergic rhinitis on dental and skeletal development: a comparison of sibling pairs. Am J Orthod Dentofacial Orthop 1987; 92:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/87\">",
"      Carra MC, Huynh N, Morton P, et al. Prevalence and risk factors of sleep bruxism and wake-time tooth clenching in a 7- to 17-yr-old population. Eur J Oral Sci 2011; 119:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/88\">",
"      Bayardo RE, Mejia JJ, Orozco S, Montoya K. Etiology of oral habits. ASDC J Dent Child 1996; 63:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/89\">",
"      Widmalm SE, Christiansen RL, Gunn SM. Oral parafunctions as temporomandibular disorder risk factors in children. Cranio 1995; 13:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/90\">",
"      Kieser JA, Groeneveld HT. Relationship between juvenile bruxing and craniomandibular dysfunction. J Oral Rehabil 1998; 25:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/91\">",
"      Vanderas AP, Menenakou M, Kouimtzis T, Papagiannoulis L. Urinary catecholamine levels and bruxism in children. J Oral Rehabil 1999; 26:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/92\">",
"      Weideman CL, Bush DL, Yan-Go FL, et al. The incidence of parasomnias in child bruxers versus nonbruxers. Pediatr Dent 1996; 18:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19320/abstract/93\">",
"      Rugh JD, Harlan J. Nocturnal bruxism and temporomandibular disorders. Adv Neurol 1988; 49:329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6277 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19320=[""].join("\n");
var outline_f18_55_19320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15700743\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONNUTRITIVE SUCKING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15700700\">",
"      Overview of effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dental effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Otitis media",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - SIDS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Miscellaneous effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15700707\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15706307\">",
"      - Pacifier use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15700715\">",
"      - Breaking the habit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MOUTH-BREATHING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15700722\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15700729\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15700736\">",
"      Orofacial effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Narrow upper arch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mandibular rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H120458254\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      BRUXISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15700743\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37846?source=related_link\">",
"      Paronychia and ingrown toenails",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33192?source=related_link\">",
"      Preventive dental care and counseling for infants and young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_55_19321="Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment";
var content_f18_55_19321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/55/19321/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19321/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/55/19321/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19321/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19321/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/55/19321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19321/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/55/19321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H811222\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multistate outbreak of fungal central nervous system (CNS) infection and septic arthritis was detected in the United States in late September 2012. Currently, at least 700 patients who received epidural injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    produced at a single compounding center (New England Compounding Center) have developed meningitis with or without posterior circulation stroke",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spinal or paraspinal infections, and more than 30 patients who received intra-articular injections of the same drug have developed osteoarticular infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Exserohilum spp, a dematiaceous (brown-black) fungus, has been the most commonly identified fungus (",
"    <a class=\"graphic graphic_picture graphicRef86772 \" href=\"UTD.htm?37/55/38769\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The United States Centers for Disease Control and Prevention (CDC) has issued recommendations for the management of patients affected by the outbreak. These recommendations can be found on the",
"    <a class=\"external\" href=\"file://www.cdc.gov/HAI/outbreaks/meningitis.html\">",
"     CDC&rsquo;s web site",
"    </a>",
"    and are expected to be updated frequently during the outbreak investigation. Our recommendations are in keeping with those of the CDC.",
"   </p>",
"   <p>",
"    The treatment of patients with fungal CNS infection or septic arthritis associated with the outbreak will be reviewed here; the epidemiology, clinical manifestations, and diagnosis of such infections are presented separately. The treatment of infections due to dematiaceous fungi and Aspergillus spp that are not associated with the outbreak are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=see_link\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43894?source=see_link\">",
"     \"Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H672980052\">",
"    <span class=\"h1\">",
"     CASE DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC) has defined a",
"    <strong>",
"     probable case",
"    </strong>",
"    associated with the 2012 outbreak as a person who received an injection with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    acetate that was definitely or likely produced by the New England Compounding Center (NECC) after May 21, 2012, and who has developed",
"    <strong>",
"     any",
"    </strong>",
"    of the following syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningitis of unknown etiology following epidural or paraspinal injection.",
"      <strong>",
"      </strong>",
"      Clinically diagnosed meningitis is defined as the presence of one or more of the following symptoms: headache, fever, stiff neck, or photophobia",
"      <strong>",
"       and",
"      </strong>",
"      a cerebrospinal fluid (CSF) profile showing pleocytosis (&gt;5 white blood cells, adjusting for the presence of red blood cells by subtracting 1 white blood cell for every 500 red blood cells), regardless of glucose or protein concentration.",
"     </li>",
"     <li>",
"      Posterior circulation stroke without a cardioembolic source without documentation of a normal CSF profile following epidural or paraspinal injection.",
"     </li>",
"     <li>",
"      Osteomyelitis, abscess, or other infection (eg, soft tissue infection) of unknown etiology in the spinal or paraspinal structures at or near the site of epidural or paraspinal injection. Paraspinal injections include, but are not limited to, spinal facet joint injection, sacroiliac joint injection, and spinal or paraspinal nerve",
"      <span class=\"nowrap\">",
"       root/ganglion",
"      </span>",
"      block.",
"     </li>",
"     <li>",
"      Osteomyelitis or worsening inflammatory arthritis of a peripheral joint (eg, knee, shoulder, or ankle) of unknown etiology diagnosed following joint injection. Clinically diagnosed septic arthritis is defined as new or worsening pain with presence of new or worsening effusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"       \"Septic arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A",
"    <strong>",
"     confirmed case",
"    </strong>",
"    is defined as a probable case with evidence of a fungal pathogen (by culture, histopathology, molecular, or antigen-based assay) associated with one of the clinical syndromes described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811229\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC) has issued treatment recommendations for patients affected by the outbreak [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Our recommendations are consistent with those of the CDC. Updated information regarding management can be found on the",
"    <a class=\"external\" href=\"file://www.cdc.gov/hai/outbreaks/clinicians/guidance_cns.html\">",
"     CDC&rsquo;s web site",
"    </a>",
"    . Treatment recommendations are based on case reports, in vitro susceptibility data, and the pharmacokinetics of the available antifungal agents.",
"   </p>",
"   <p>",
"    The site of infection (central nervous system [CNS] versus peripheral joint) is an important consideration when determining the appropriate therapy.",
"   </p>",
"   <p>",
"    The CDC has established a volunteer Clinicians Consultation Network of experts in the treatment of invasive fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/6\">",
"     6",
"    </a>",
"    ]. These clinicians are available for consultation. The service can be accessed by calling 1-800-CDC-INFO (1-800-232-4636).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811236\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consult an infectious diseases specialist to assist with the diagnosis, management, and follow-up, which may be complex and prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Since information about the outbreak continues to evolve, treatment recommendations will continue to change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811243\">",
"    <span class=\"h3\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     Updated information regarding management can be found on the",
"    </strong>",
"    <a class=\"external\" href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\">",
"     CDC&rsquo;s web site",
"    </a>",
"    <strong>",
"     and clinicians should check this web site before initiating therapy.",
"    </strong>",
"    After collecting cerebrospinal fluid (CSF) for culture and other studies, initiate empiric antifungal therapy in addition to routine empiric treatment for other potential pathogens until the etiology of the infection has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4\">",
"     4",
"    </a>",
"    ]. It is important to note that patients should receive empiric antifungal therapy if they meet the case definition of either probable or confirmed fungal meningitis (see",
"    <a class=\"local\" href=\"#H672980052\">",
"     'Case definitions'",
"    </a>",
"    above). Exserohilum spp and certain other fungi may grow slowly, and in many cases have not been detected at all, even with molecular detection methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=see_link&amp;anchor=H19514050#H19514050\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis\", section on 'Evaluation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who meet the case definition of probable or confirmed fungal meningitis associated with a contaminated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    epidural injection (see",
"    <a class=\"local\" href=\"#H672980052\">",
"     'Case definitions'",
"    </a>",
"    above), the CDC currently (as of April 10, 2013) recommends antifungal therapy with",
"    <strong>",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    <strong>",
"     with or without",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    <strong>",
"     (AmBisome)",
"    </strong>",
"    as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      should be given at 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours, which is a higher dose than is typical for other fungal infections. The same dosing is recommended regardless of whether voriconazole is being given IV or orally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      is recommended because ensuring rapid and adequate penetration of the CNS is essential. In addition, the high dose should allow adequate blood levels to be attained quickly. We suggest that patients continue on a high dose for the duration of treatment, if possible.",
"     </li>",
"     <li>",
"      For most patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      should be given IV initially. Patients who are initially given IV voriconazole can be switched to oral voriconazole once they are stable and improving if they have no contraindications to oral therapy. Patients with mild disease who are able to take oral voriconazole and who can be monitored closely can be given oral voriconazole for initial therapy at the clinician&rsquo;s discretion. Oral voriconazole has excellent bioavailability, exceeding 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/7\">",
"       7",
"      </a>",
"      ]. Thus, the target voriconazole trough concentration can be achieved using oral voriconazole, but it may require a slightly higher dose or may take longer to achieve than the IV formulation if problems with absorption occur. Oral voriconazole should be taken at least one hour before or after a meal.",
"     </li>",
"     <li>",
"      Patients with meningitis who are severely ill (eg, severe headache",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meningismus, altered mental status,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant pleocytosis) should be given IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      initially, whereas those who have mild signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms (eg, mild headache, normal mental status, and mild pleocytosis) can be started on oral voriconazole (at the same weight-based dosing).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      has good CNS penetration [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/8-10\">",
"       8-10",
"      </a>",
"      ], with CSF concentrations ranging from 22 to 100 percent of serum concentrations (median 46 percent) in a study that assessed 36 CSF samples from 14 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/9\">",
"       9",
"      </a>",
"      ]. Among five patients in this outbreak, CSF voriconazole concentrations were approximately 50 percent of serum concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/11\">",
"       11",
"      </a>",
"      ]. Among the azoles with activity against molds (voriconazole,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      ), voriconazole has the best CNS penetration [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/12\">",
"       12",
"      </a>",
"      ]. Voriconazole concentrations in both the serum and CSF exceed the minimum inhibitory concentration for many dematiaceous fungi [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H8#H8\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment and prevention of invasive aspergillosis\", section on 'Voriconazole'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is anticipated that many patients could have neurologic symptoms, such as hallucinations, and visual changes (changes in color vision, photopsia), on the high dosage of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      . The development of hallucinations has been associated with high serum voriconazole concentrations and can be frightening to patients. Dose reduction will be required if this occurs. In contrast, the visual changes are usually benign and dose reduction is not necessary. However, these visual changes can interfere with driving a motor vehicle.",
"     </li>",
"     <li>",
"      Dose adjustments may be necessary in certain patients, such as children (who may require a higher dose), patients with hepatic impairment (who may require a lower dose), and those who appear to be",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      hypermetabolizers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with meningitis who are severely ill (eg, severe headache",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meningismus, altered mental status,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant pleocytosis) and for patients who do not improve or who worsen clinically (including developing a new site of infection) on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      monotherapy, we suggest combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (AmBisome; 5 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 24 hours)",
"      <strong>",
"       plus",
"      </strong>",
"      IV voriconazole (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours). A higher dose of liposomal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 24 hours) can be given to patients who are not improving with the initial dosing, but clinicians should be aware of the increased risk of nephrotoxicity with the higher dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The liposomal preparation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      is preferred over other lipid formulations for CNS infections because it appears to achieve higher concentrations in the brain compared with other lipid formulations or amphotericin B deoxycholate (based on animal data) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nephrotoxicity is a common complication of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      therapy, even with the lipid formulations. Administration of normal saline prior to infusion should be used to minimize the risk of nephrotoxicity; we suggest 1 liter of normal saline for patients who can tolerate it. For patients who cannot tolerate such a large fluid bolus, we suggest giving 500 mL of normal saline if possible. Hypokalemia and hypomagnesemia have been especially problematic, and supplementation of these electrolytes is essential.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are unable to tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      monotherapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (5 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 24 hours) can be used as an alternative to voriconazole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who develop non-severe adverse effects (eg, visual changes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or minor elevations in creatinine with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    ), first-line therapy can be continued in many cases, with dose reduction as indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4\">",
"     4",
"    </a>",
"    ]. In patients who have had a severe adverse reaction to voriconazole",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and who have a contraindication to the other first-line agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    can be used, but the decision to change the antifungal regimen should be made in consultation with an infectious diseases specialist experienced in the treatment of invasive fungal infections. It is important to note that posaconazole and itraconazole have variable pharmacokinetics in the CNS and their effectiveness for the treatment of infections associated with the outbreak has not been established.",
"   </p>",
"   <p>",
"    Monitoring during therapy is discussed below. (See",
"    <a class=\"local\" href=\"#H811264\">",
"     'Monitoring during therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend the use of intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    due to limited data on its efficacy or associated toxicities. We also do",
"    <strong>",
"     not",
"    </strong>",
"    recommend adjuvant glucocorticoid therapy since its efficacy has not been proven and it may be harmful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811250\">",
"    <span class=\"h3\">",
"     Injection site (parameningeal) infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     Updated information regarding management can be found on the",
"    </strong>",
"    <a class=\"external\" href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\">",
"     CDC&rsquo;s web site",
"    </a>",
"    <strong>",
"     and clinicians should check this web site before initiating therapy.",
"    </strong>",
"    The CDC currently (as of April 10, 2013) recommends that most patients with epidural abscess, phlegmon, discitis, vertebral osteomyelitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arachnoiditis, initially receive IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    at a dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours, which is a higher dose than is typical for other fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Patients can be switched to oral voriconazole once they are stable and improving if they are expected to have adequate oral absorption. Patients with mild disease who are able to take oral voriconazole and who can be monitored closely can be given oral voriconazole for initial therapy at the clinician&rsquo;s discretion. Other considerations regarding the use of voriconazole are discussed above. (See",
"    <a class=\"local\" href=\"#H811243\">",
"     'Meningitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who develop MRI findings of an epidural abscess, epidural phlegmon, vertebral osteomyelitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arachnoiditis while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    for meningitis, we suggest adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    5 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily to the antifungal regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4\">",
"     4",
"    </a>",
"    ]. For patients who have disease progression on voriconazole monotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who are clinically unstable, combination therapy with liposomal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (AmBisome)",
"    <strong>",
"     plus",
"    </strong>",
"    voriconazole should be considered.",
"   </p>",
"   <p>",
"    Patients with osteomyelitis will likely require a longer duration of therapy than patients with meningitis (see",
"    <a class=\"local\" href=\"#H811271\">",
"     'Duration of therapy'",
"    </a>",
"    below). A neurosurgeon should be consulted early for patients with epidural abscess, phlegmon, discitis, vertebral osteomyelitis, or arachnoiditis. Patients with epidural abscesses may require operative debridement in addition to antifungal therapy. Those who have arachnoiditis have generally been treated with antifungal therapy and have not had operative intervention. Monitoring during therapy is discussed below. (See",
"    <a class=\"local\" href=\"#H811264\">",
"     'Monitoring during therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811257\">",
"    <span class=\"h3\">",
"     Osteoarticular infection not involving the spine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     Updated information regarding management can be found on the",
"    </strong>",
"    <a class=\"external\" href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\">",
"     CDC&rsquo;s web site",
"    </a>",
"    <strong>",
"     and clinicians should check this web site before initiating therapy.",
"    </strong>",
"    Routine antibacterial therapy for septic arthritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteomyelitis should be given according to the judgment of the treating clinician while awaiting results of diagnostic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/5\">",
"     5",
"    </a>",
"    ]. In patients with septic arthritis who are clinically stable, it is reasonable to wait for 48 to 72 hours before starting empiric antifungal therapy to allow time for the identification of alternative processes (eg, bacterial arthritis, crystal-induced arthritis).",
"   </p>",
"   <p>",
"    When antifungal therapy is initiated for patients who meet the case definition of probable or confirmed fungal osteoarticular infection not involving the spine associated with a contaminated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    epidural injection (see",
"    <a class=\"local\" href=\"#H672980052\">",
"     'Case definitions'",
"    </a>",
"    above), the CDC currently (as of April 10, 2013) recommends antifungal therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    <strong>",
"     with or without a lipid formulation of",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    <strong>",
"    </strong>",
"    as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      should be given beginning with a loading dose of 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours for two doses, followed by 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours thereafter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients who have severe osteoarticular infection should be started on IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , but those with mild infection may be started on oral voriconazole. Voriconazole has excellent penetration into the joint space [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who are initially given IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      can be switched to oral voriconazole once they are stable and improving if they are expected to have adequate oral absorption. Dose adjustments may be necessary in certain patients, such as children (who may require a higher dose), patients with hepatic impairment (who may require a lower dose), and those who appear to be voriconazole hypermetabolizers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with osteoarticular infection who have disease progression on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      monotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who are clinically unstable, combination therapy with a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      [AmBisome],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      [ABLC, Abelcet])",
"      <strong>",
"       plus",
"      </strong>",
"      voriconazole should be considered. When a lipid formulation of amphotericin B is used, it should be given at a dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 24 hours. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link&amp;anchor=H16#H16\">",
"       \"Pharmacology of amphotericin B\", section on 'Lipid-based amphotericin B formulations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nephrotoxicity is a common complication of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      therapy, even with the lipid formulations. Administration of normal saline prior to infusion should be used to minimize the risk of nephrotoxicity; we suggest 1 liter of normal saline for patients who can tolerate it. For patients who cannot tolerate such a large fluid bolus, we suggest giving 500 mL of normal saline if possible. Hypokalemia and hypomagnesemia have been especially problematic, and supplementation of these electrolytes is essential.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternative therapies for patients who have osteoarticular infection and who are unable to tolerate treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      include lipid formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be used since it lacks activity against Exserohilum. Serum concentrations of posaconazole and itraconazole must be monitored when these agents are used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H30#H30\">",
"       \"Pharmacology of azoles\", section on 'Posaconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H27#H27\">",
"       \"Pharmacology of azoles\", section on 'Itraconazole'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monitoring during therapy is discussed below. (See",
"    <a class=\"local\" href=\"#H811264\">",
"     'Monitoring during therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to antifungal therapy, in patients with severe septic arthritis (based on clinical findings or diagnostic testing), consideration of arthroscopy with joint lavage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    debridement by an orthopedic surgeon is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=see_link&amp;anchor=H101033353#H101033353\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis\", section on 'Osteoarticular infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811264\">",
"    <span class=\"h2\">",
"     Monitoring during therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be monitored closely during therapy for adverse effects and drug-drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4,6,13\">",
"     4,6,13",
"    </a>",
"    ]. Although the appropriate frequency of laboratory and symptom monitoring will vary from patient to patient depending on comorbidities and the development of toxicities, we suggest the following frequencies of testing as general guidelines for patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , we suggest at least weekly monitoring of liver function tests because voriconazole can be hepatotoxic. Patients should also be counseled about the risk of hepatotoxicity and the signs and symptoms of hepatitis (eg, nausea, right upper quadrant pain, jaundice). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H12#H12\">",
"       \"Pharmacology of azoles\", section on 'Hepatotoxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest checking a trough concentration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      on the fifth day of therapy; the dose should be adjusted to attain a trough concentration of &gt;2",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      and &lt;5",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4\">",
"       4",
"      </a>",
"      ]. Trough concentrations below 2",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      warrant an increase in the voriconazole dose. On the other hand, serum drug concentrations above 5",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      warrant a reduction in the voriconazole dose, because they have been associated with an increased risk of hepatotoxicity and neurotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/6,15,16\">",
"       6,15,16",
"      </a>",
"      ]. Once the target trough concentration has been reached, trough concentrations should be checked weekly for the initial four to six weeks of therapy and the dose should be adjusted to maintain a trough concentration within the goal range. These recommendations apply to patients receiving either the IV or oral formulation of voriconazole. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H28#H28\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinicians should monitor patients for toxicities, not just",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      levels [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4\">",
"       4",
"      </a>",
"      ]. We suggest careful questioning of the patient about neurologic symptoms. As noted above, it is anticipated that many patients could have hallucinations and visual changes (changes in color vision, photopsia), particularly on the high dosage of voriconazole. The development of hallucinations has been associated with high serum voriconazole concentrations and can be frightening to patients. If a patient has hallucinations, a serum voriconazole trough concentration should be checked promptly and the voriconazole dose should be reduced if it is &gt;5",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      In contrast, the visual changes are usually benign and dose reduction is not necessary. However, these visual changes can interfere with driving a motor vehicle.",
"     </li>",
"     <li>",
"      In patients at risk for QT prolongation (eg, known QT prolongation, concomitant medications that can prolong the QT interval [eg, fluoroquinolones,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ], hypokalemia, hypomagnesemia), the QTc should be evaluated at baseline and periodically during therapy since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      can prolong the QT interval. The risk of QT prolongation may be worsened by the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      since it can cause hypokalemia and hypomagnesemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H23#H23\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H34#H34\">",
"       \"Pharmacology of azoles\", section on 'Selected clinical effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      has many important drug-drug interactions that clinicians must consider when initiating therapy or altering the dose. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"       \"Pharmacology of azoles\", section on 'Drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients receiving a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , we suggest daily monitoring of renal function and electrolytes since amphotericin B formulations can cause acute kidney injury and electrolyte wasting. Potassium wasting can be severe and must be monitored closely because of the risk of QTc prolongation. Clinicians should also be aware that lipid formulations of amphotericin B can cause infusion-related reactions, including chest pain, dyspnea, hypoxia, abdominal pain, flushing, and urticaria. Among 35 patients affected by the outbreak at one center who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      , this agent was discontinued in 34 patients (97 percent) after a median of 4 days (range 1 to 25 days) primarily due to nephrotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"       \"Amphotericin B nephrotoxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link&amp;anchor=H16#H16\">",
"       \"Pharmacology of amphotericin B\", section on 'Lipid-based amphotericin B formulations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has been concern about the potential for nephrotoxicity of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in patients with renal dysfunction because the IV formulation contains sulphobutylether-beta-cyclodextrin (SBECD); SBECD is a solubilizing agent that is renally cleared and that has been associated with nephrotoxicity in rats as a result of renal tubule vacuolation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The manufacturer has recommended that IV voriconazole generally be avoided in patients with renal insufficiency (CrCl &lt;50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/7\">",
"     7",
"    </a>",
"    ]. However, in a retrospective study that evaluated renal function in 166 patients receiving IV or oral voriconazole (one-quarter of whom had a glomerular filtration rate &lt;50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at baseline and received IV voriconazole), neither baseline renal function nor route of administration was associated with worsening renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/20\">",
"     20",
"    </a>",
"    ]. During the current outbreak, IV voriconazole is recommended for patients who require it even if renal insufficiency is present [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H16#H16\">",
"     \"Pharmacology of azoles\", section on 'Voriconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811271\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate duration of therapy has not been established and will vary depending on individual patient circumstances and the severity and location of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with meningitis alone, therapy will likely be required for a",
"      <strong>",
"       minimum",
"      </strong>",
"      of three months.",
"     </li>",
"     <li>",
"      For patients with injection site (parameningeal) infection, therapy will likely be required for a",
"      <strong>",
"       minimum",
"      </strong>",
"      of three to six months.",
"     </li>",
"     <li>",
"      For patients with severe CNS and parameningeal disease, including stroke, arachnoiditis, osteomyelitis, and discitis, and for those who have underlying immunosuppression or persistent CSF abnormalities, therapy will likely need to be continued for six months to one year.",
"     </li>",
"     <li>",
"      For patients with osteoarticular infections not involving the spine, the duration of therapy is not known, but a minimum of three and possibly six months may be needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to tailor or discontinue therapy will depend in part on the patient&rsquo;s response to therapy. Decisions about the duration of therapy should be made in consultation with an infectious diseases specialist who is experienced with the management of invasive fungal infections. After completion of therapy, clinicians should be vigilant for potential relapse of infection.",
"   </p>",
"   <p>",
"    Because the appropriate duration of therapy and the potential for relapse are unknown, it is essential to closely monitor patients in whom antifungal therapy has been discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with recurrent symptoms or worsening pain should be evaluated immediately. Clinicians should have a low threshold for performing a lumbar puncture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging to detect relapsed infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811278\">",
"    <span class=\"h2\">",
"     Evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the rarity of infections caused by Exserohilum spp and other dematiaceous fungi, there are no randomized trials that have evaluated the optimal therapy of invasive infections, and clinical experience is limited. In addition, susceptibility testing of the dematiaceous fungi has not been standardized, but Exserohilum spp appear to be susceptible in vitro to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , but",
"    <strong>",
"     not",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/5,21\">",
"     5,21",
"    </a>",
"    ]. Voriconazole has excellent bioavailability and good CNS penetration, as discussed above (see",
"    <a class=\"local\" href=\"#H811243\">",
"     'Meningitis'",
"    </a>",
"    above). Neither posaconazole nor itraconazole achieve substantial levels in the CSF and their oral absorption is unpredictable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports from prior to the outbreak have described successful treatment in some patients with Exserohilum spp infections with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. Other patients have died despite therapy; immunosuppression is likely to have contributed to mortality in cases not associated with the 2012 outbreak [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811299\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes of patients affected by the outbreak of fungal meningitis and septic arthritis have not yet been determined. As of April 8, 2013, among the 700 patients diagnosed with central nervous system infection as part of the outbreak, 53 (7.6 percent) have died [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/2\">",
"     2",
"    </a>",
"    ]. In a study that included eight fatal cases, seven had stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19321/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/6/36962?source=see_link\">",
"       \"Patient information: Fungal meningitis and septic arthritis outbreak (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H811313\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multistate outbreak of fungal central nervous system (CNS) infection and septic arthritis was detected in the United States in late September 2012. Currently, at least 700 patients who received epidural injections of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      produced at a single compounding center (New England Compounding Center) have developed meningitis with or without posterior circulation stroke",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spinal or paraspinal infections and more than 30 patients who received intra-articular injections of the same drug have developed osteoarticular infections. Updated case counts can be found on the",
"      <a class=\"external\" href=\"file://www.cdc.gov/hai/outbreaks/meningitis-map.html\">",
"       United States Centers for Disease Control and Prevention&rsquo;s (CDC's) web site",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=see_link\">",
"       \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The CDC has issued treatment recommendations for patients affected by the outbreak. Since information about the outbreak is rapidly evolving, treatment recommendations will continue to change. Updated information regarding management can be found on the",
"      <a class=\"external\" href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\">",
"       CDC&rsquo;s web site",
"      </a>",
"      and clinicians should check this web site before initiating therapy. (See",
"      <a class=\"local\" href=\"#H811229\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients who meet the case definition of probable or confirmed fungal meningitis associated with a contaminated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      epidural injection should be given antifungal therapy",
"      <strong>",
"       immediately",
"      </strong>",
"      .",
"      <strong>",
"       In accordance with the CDC&rsquo;s recommendations (as of April 10, 2013),",
"      </strong>",
"      such patients should receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with",
"      <strong>",
"       meningitis who have mild signs",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       symptoms",
"      </strong>",
"      (eg, mild headache, normal mental status, and mild pleocytosis), we suggest monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); the dose of voriconazole should be 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV or orally every 12 hours.",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       meningitis who are severely ill",
"      </strong>",
"      (eg, severe headache",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meningismus, altered mental status,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant pleocytosis)",
"      <strong>",
"       and",
"      </strong>",
"      <strong>",
"       patients who do not improve or who worsen clinically",
"      </strong>",
"      on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      monotherapy, we suggest combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      voriconazole (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); the dose of liposomal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      should be 5 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 24 hours and the dose of voriconazole should be 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours. (See",
"      <a class=\"local\" href=\"#H672980052\">",
"       'Case definitions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H811243\">",
"       'Meningitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       In accordance with the CDC&rsquo;s recommendations (as of April 10, 2013),",
"      </strong>",
"      when antifungal therapy is initiated for patients who meet the case definition of probable or confirmed fungal osteoarticular infection associated with a contaminated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      injection (see",
"      <a class=\"local\" href=\"#H672980052\">",
"       'Case definitions'",
"      </a>",
"      above), patients should receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      with or without a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients with",
"      <strong>",
"       osteoarticular infection not involving the spine",
"      </strong>",
"      , we suggest monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); voriconazole should be given as a loading dose of 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV or orally every 12 hours for two doses, followed by 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV or orally every 12 hours thereafter. In patients with septic arthritis who are clinically stable, it is reasonable to wait for 48 to 72 hours before starting empiric antifungal therapy to allow time for the identification of alternative processes. (See",
"      <a class=\"local\" href=\"#H811257\">",
"       'Osteoarticular infection not involving the spine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       injection site infections involving the spine",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       parameningeal structures (vertebral osteomyelitis, epidural abscess, phlegmon, discitis,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       arachnoiditis)",
"      </strong>",
"      , we suggest monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); voriconazole should be given at a dose of 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours. Patients can be switched to oral voriconazole once they are stable and improving if they are expected to have adequate oral absorption. If an injection site infection occurs in a patient already receiving voriconazole for meningitis or if such a patient has disease progression on voriconazole monotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      is clinically unstable, we suggest giving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      in addition to voriconazole; liposomal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      should be given at a dose of 5 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 24 hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H811250\">",
"       'Injection site (parameningeal) infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       osteoarticular infection",
"      </strong>",
"      <strong>",
"       who have disease progression on",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      <strong>",
"       monotherapy",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       who are clinically unstable",
"      </strong>",
"      , we suggest that a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      be added to voriconazole (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); a lipid formulation of amphotericin B should be dosed at 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 24 hours. (See",
"      <a class=\"local\" href=\"#H811257\">",
"       'Osteoarticular infection not involving the spine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Close monitoring for adverse effects (eg, hepatotoxicity, neurotoxicity, and QT prolongation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ; acute kidney injury and electrolyte wasting with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      ) is essential. (See",
"      <a class=\"local\" href=\"#H811264\">",
"       'Monitoring during therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with meningitis alone will likely require a",
"      <strong>",
"       minimum",
"      </strong>",
"      of three months of therapy. Patients with injection site (parameningeal) infection will likely require a",
"      <strong>",
"       minimum",
"      </strong>",
"      of three to six months of therapy. Patients with severe CNS or injection site disease, including stroke, arachnoiditis, osteomyelitis, discitis, and those who have underlying immunosuppression or persistent CSF abnormalities will likely need to continue therapy for six months to one year. For patients with osteoarticular infections not involving the spine, a minimum of three months and possibly six months of therapy may be needed. The decision to tailor or discontinue therapy will depend in part on the patient&rsquo;s response to therapy and should be made in consultation with an infectious diseases specialist who has experience with invasive fungal infection. (See",
"      <a class=\"local\" href=\"#H811271\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy - United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:839.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Multistate fungal meningitis outbreak - current case count. file://www.cdc.gov/hai/outbreaks/meningitis-map.html (Accessed on April 10, 2013).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Case definitions for meningitis and septic arthritis. file://www.cdc.gov/hai/outbreaks/clinicians/casedef_multistate_outbreak.html (Accessed on October 31, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Interim treatment guidance for central nervous system and parameningeal infections associated with injection of contaminated steroid products. file://www.cdc.gov/hai/outbreaks/clinicians/guidance_cns.html (Accessed on March 06, 2013).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Interim treatment guidance for osteoarticular infections associated with injection of contaminated steroid products. file://www.cdc.gov/hai/outbreaks/clinicians/interim_treatment_options_septic_arthritis.html (Accessed on October 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/6\">",
"      Shoham S, Marr KA. Treatment of iatrogenic fungal infections: a black mold defines a new gray zone in medicine. Ann Intern Med 2013; 158:208.",
"     </a>",
"    </li>",
"    <li>",
"     VFEND IV (voriconazole) for injection, VFEND tablets (voriconazole), VFEND (voriconazole) oral suspension prescribing information. file://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021266s023,021267s024,021630s013lbl.pdf (Accessed on October 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/8\">",
"      Weiler S, Fiegl D, MacFarland R, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011; 55:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/9\">",
"      Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/10\">",
"      Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/11\">",
"      Kerkering TM, Grifasi ML, Baffoe-Bonnie AW, et al. Early clinical observations in prospectively followed patients with fungal meningitis related to contaminated epidural steroid injections. Ann Intern Med 2013; 158:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/12\">",
"      Nau R, S&ouml;rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/13\">",
"      Kauffman CA, Pappas PG, Patterson TF. Fungal Infections Associated with Contaminated Methylprednisolone Injections - Preliminary Report. N Engl J Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/14\">",
"      Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/15\">",
"      Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/16\">",
"      Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/17\">",
"      Kainer MA, Reagan DR, Nguyen DB, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med 2012; 367:2194.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Antiviral Drugs Advisory Committee. Briefing document for voriconazole",
"(oral and intravenous formulations). file://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_pfizer.pdf (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/19\">",
"      Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci 2010; 99:3291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/20\">",
"      Neofytos D, Lombardi LR, Shields RK, et al. Administration of voriconazole in patients with renal dysfunction. Clin Infect Dis 2012; 54:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/21\">",
"      da Cunha KC, Sutton DA, Gen&eacute; J, et al. Molecular identification and in vitro response to antifungal drugs of clinical isolates of Exserohilum. Antimicrob Agents Chemother 2012; 56:4951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/22\">",
"      Derber C, Elam K, Bearman G. Invasive sinonasal disease due to dematiaceous fungi in immunocompromised individuals: case report and review of the literature. Int J Infect Dis 2010; 14 Suppl 3:e329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/23\">",
"      Adler A, Yaniv I, Samra Z, et al. Exserohilum: an emerging human pathogen. Eur J Clin Microbiol Infect Dis 2006; 25:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/24\">",
"      Lin SC, Sun PL, Ju YM, Chan YJ. Cutaneous phaeohyphomycosis caused by Exserohilum rostratum in a patient with cutaneous T-cell lymphoma. Int J Dermatol 2009; 48:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/25\">",
"      Aquino VM, Norvell JM, Krisher K, Mustafa MM. Fatal disseminated infection due to Exserohilum rostratum in a patient with aplastic anemia: case report and review. Clin Infect Dis 1995; 20:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy--United States, July-November 2002. MMWR Morb Mortal Wkly Rep 2002; 51:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19321/abstract/27\">",
"      Perfect JR. Iatrogenic fungal meningitis: tragedy repeated. Ann Intern Med 2012; 157:825.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87286 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-210.101.131.231-93E8FEEFE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19321=[""].join("\n");
var outline_f18_55_19321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H811313\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H811222\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H672980052\">",
"      CASE DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H811229\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H811236\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H811243\">",
"      - Meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H811250\">",
"      - Injection site (parameningeal) infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H811257\">",
"      - Osteoarticular infection not involving the spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H811264\">",
"      Monitoring during therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H811271\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H811278\">",
"      Evidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H811299\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H811313\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/87286\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/87286|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/55/38769\" title=\"picture 1\">",
"      Exserohilum rostratum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43894?source=related_link\">",
"      Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=related_link\">",
"      Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/6/36962?source=related_link\">",
"      Patient information: Fungal meningitis and septic arthritis outbreak (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_55_19322="Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy";
var content_f18_55_19322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/55/19322/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19322/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19322/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/55/19322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19322/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/55/19322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/55/19322/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/55/19322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias are common in patients with heart failure (HF) and cardiomyopathy, ranging from asymptomatic ventricular premature beats (VPBs) to sustained ventricular tachycardia (VT) or ventricular fibrillation (VF), which can lead to sudden cardiac death (SCD).",
"   </p>",
"   <p>",
"    The secondary and primary prevention of SCD in patients with HF and cardiomyopathy will be reviewed here, with emphasis on the role of implantable cardioverter-defibrillators. The different types of ventricular arrhythmias, syncope, the effects of HF therapy on ventricular arrhythmias, and the role of electrophysiologic testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of related issues are presented elsewhere. These include ventricular arrhythmias in patients with an acute or prior MI, and ventricular arrhythmias related to other forms of cardiomyopathy, such as hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy and isolated left ventricular noncompaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=see_link\">",
"     \"Isolated left ventricular noncompaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF DEATH IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact percentages vary with the severity of disease, but progressive pump failure, unexpected SCD, and SCD during episodes of clinical worsening of HF each account for approximately one-third of deaths in HF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/1\">",
"     1",
"    </a>",
"    ]. VT degenerating into VF is the most common cause of SCD, although bradyarrhythmias are responsible in 5 to 33 percent of cases of SCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link&amp;anchor=H27#H27\">",
"     \"Prognosis of heart failure\", section on 'Causes of death in HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More severe HF is associated with a higher overall mortality rate and a higher absolute rate of SCD, but a decreasing proportion of SCD to total deaths. This was illustrated in the MERIT-HF trial in which patients in NYHA class II, III and IV had increasing rates of SCD at one year (6.3, 10.5, and 18.6 percent, respectively), but a decreasing percentage of deaths that were classified as SCD (64, 59, and 33 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have provided support for the concept that not all sudden deaths in patients with HF are due to arrhythmia, which are the only deaths that might be prevented with an implantable cardioverter-defibrillator (ICD):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the AIRE trial, 45 percent of patients who died suddenly had severe or worsening HF prior to their death; only 39 percent of these sudden deaths were thought to be due to arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The control arm of the MADIT II trial included 72 deaths considered to be cardiac: 31 percent occurred within one hour of symptom onset, 36 percent occurred more than one hour after symptom onset, and 33 percent were unwitnessed [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/4\">",
"       4",
"      </a>",
"      ]. In the ICD arm, defibrillator therapy reduced the incidence of deaths occurring within one hour of symptoms and unwitnessed deaths, suggesting that these groups included most of the patients with terminal arrhythmia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Guideline recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines on the management of ventricular arrhythmias and sudden cardiac death and the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities recommended an ICD in survivors of SCD; patients with stable sustained VT are also at increased risk for SCD and it was concluded that such patients should receive an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential complication of ICD therapy is electrical storm, which refers to multiple recurrences of ventricular arrhythmias (VT or VF) over a short period of time (eg, three or more episodes during a 24 hour period). The incidence of electrical storm appears to be higher among patients receiving ICDs for secondary prevention than among those receiving ICDs for primary prevention. The implications and treatment of electrical storm are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H20#H20\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Electrical storm'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Adjunctive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SECONDARY PREVENTION OF SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HF or cardiomyopathy who survive an episode of sudden cardiac arrest (SCA) or experience sustained VT are at high risk of future arrhythmic events and SCD. Such patients are usually treated with an ICD for the secondary prevention of SCD. Although some patients are treated with other therapies, such as antiarrhythmic drugs, radiofrequency ablation, surgery, and cardiac transplantation, none of these approaches is as effective as an ICD for improving survival. For this reason, they are used either as an adjunct to an ICD or as an alternative in patients who are not candidates for ICD therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Use of an ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with HF or cardiomyopathy who have serious ventricular arrhythmias (sustained VT or VF) are candidates for an ICD. The indications for ICD implantation for secondary prevention of SCD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H19#H19\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial observational studies suggested that an ICD improved outcomes in survivors of SCD who had LV dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. These observations provided the rationale for the performance of randomized controlled trials. Three major trials (CASH, CIDS, and, AVID) and several meta-analyses compared an ICD to pharmacologic therapy in survivors of SCD or other high risk patients with sustained VT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. The results of these trials are described in detail elsewhere, but are briefly summarized below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of CASH, CIDS, and AVID demonstrated a 28 percent reduction in mortality with an ICD compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (hazard ratio 0.72), due largely to a 50 percent reduction in SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/14\">",
"       14",
"      </a>",
"      ]. Although these trials were not limited to patients with HF or cardiomyopathy, a significant percentage had a reduced LVEF. In AVID, the largest trial, the mean left ventricular ejection fraction (LVEF) was 32 percent and 81 percent had coronary heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second meta-analysis, limited to 256 patients with nonischemic cardiomyopathy, reported a reduction in all-cause mortality with an ICD compared to medical therapy (relative risk 0.69, 95% CI 0.39-1.24) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/15\">",
"       15",
"      </a>",
"      ]. Although the results were not statistically significant, the number of patients was small and the magnitude of effect was similar to that seen in the above meta-analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The elevated risks of nonarrhythmic death due to HF may attenuate the benefit of an ICD in patients with severe LV dysfunction (eg, LVEF &lt;20 percent). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Causes of death in HF'",
"    </a>",
"    above.) For this reason, the benefit of ICDs in such patients has been questioned. Despite these concerns, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines do not stratify recommendations for secondary prevention of SCD based upon the LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach seems appropriate for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognostic importance of the LVEF is based upon subset analysis.",
"     </li>",
"     <li>",
"      Transvenous ICD implantation carries low risk.",
"     </li>",
"     <li>",
"      Among patients with very poor systolic function, advances in the therapy of HF have improved survival, in part due to a lower rate of nonarrhythmic death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Patients with syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the randomized trials of ICDs for the secondary prevention of SCD included patients with syncope and either spontaneous or induced sustained VT. Based upon the results of these trials, patients with HF or cardiomyopathy who have syncope and either induced or spontaneous VT are treated with an ICD for the purpose of secondary prevention of SCD.",
"   </p>",
"   <p>",
"    The role of an ICD is less clear in HF and cardiomyopathy patients with unexplained syncope (ie, in addition to a negative general evaluation, there are no spontaneous or induced ventricular arrhythmias). Observational data suggests that such patients, particularly those with severe LV dysfunction (eg, LVEF &le;30 percent), are at an increased risk of malignant arrhythmias and SCD.",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines concluded that the weight of evidence was in favor of the use of an ICD in patients with significant LV dysfunction due to nonischemic cardiomyopathy who have unexplained syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/6\">",
"     6",
"    </a>",
"    ]. However, regardless of the history of syncope, many such patients will already qualify for an ICD for primary prevention of SCD based upon SCD-HeFT criteria, and patients with ischemic cardiomyopathy and severe LV dysfunction (ie, LVEF &le;30 percent) qualify for an ICD based upon MADIT-II criteria. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Primary prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among those patients with unexplained syncope who do not already have an ICD indication, it is not clear who should receive an ICD. Based upon observational data from patients with severe LV dysfunction, we suggest ICD implantation in patients with nonischemic cardiomyopathy who have an LVEF &le;30 percent and unexplained syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Patients with ischemic cardiomyopathy and an LVEF &le;30 percent qualify for an ICD even without syncope based upon the results of the MADIT-II trial. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Primary prevention of SCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     SCD despite ICD implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the above trials of ICD therapy for the secondary prevention of SCD, approximately 20 to 35 percent of the deaths in patients with an ICD were due to arrhythmias. These deaths often result from electromechanical dissociation, also called pulseless electrical activity. However, increasingly frequent and refractory episodes of",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    may reflect the terminal stage of severe HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H4#H4\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Mechanisms of death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrical storm refers to multiple recurrences of VT or VF over a short period of time (eg, three or more episodes during a 24 hour period). Among patients with an ICD, electrical storm may trigger repeated appropriate discharges (defibrillator storm). The incidence of electrical storm appears to be higher among patients receiving an ICD for secondary prevention compared to those receiving an ICD for primary prevention. The implications and treatment of electrical storm in patients with an ICD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H20#H20\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Electrical storm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the ICD, several other pharmacologic and nonpharmacologic therapies have been evaluated in survivors of SCD. None is considered an adequate alternative to ICD therapy, but each has a role in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major randomized trials and meta-analyses cited above demonstrated that ICD therapy is superior to antiarrhythmic drugs in reducing overall mortality among SCD survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. Thus, antiarrhythmic drugs are limited to the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an adjunct to an ICD in patients with frequent arrhythmias and ICD shocks.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      are the drugs most commonly used for this purpose [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"       \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As an alternative to an ICD in patients who do not want or are not candidates for an ICD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or other beta blockers in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation (RFA) can be an effective treatment for VT, particularly when due to reentry. In patients with a prior MI, the border zone of the infarct is frequently the site of the reentrant circuit, and these sites are often amenable to ablation. In contrast, patients with nonischemic cardiomyopathy have diffuse disease and may have multiple reentrant circuits or other mechanisms of VT (eg, triggered arrhythmias) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/23\">",
"     23",
"    </a>",
"    ]. Due to the presence of more complex arrhythmic substrate, RFA is less effective in patients with nonischemic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Catheter ablation of VT is considered in three settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an adjunct to an ICD in patients who have frequent arrhythmias and ICD shocks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H12#H12\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Adjunctive therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As an alternative to an ICD in patients who do not want or are not candidates for an ICD.",
"     </li>",
"     <li>",
"      In patients with cardiomyopathy and a unique form of VT, called bundle branch reentrant VT (BBRVT). BBRVT occurs in both ischemic and nonischemic cardiomyopathy, usually with severe disease and advanced HF. Presyncope and syncope are common presenting symptoms. Catheter ablation of the right bundle branch eliminates the arrhythmia. An ICD is usually implanted after successful ablation of BBRVT because these patients are also at risk for other malignant arrhythmias due to the severity of their heart disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=see_link\">",
"       \"Bundle branch reentrant ventricular tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines recommended that patients with BBRVT should undergo electrophysiology study and ablation, and noted that most patients with BBRVT will also receive an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Arrhythmia surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reentrant VT circuits can be surgically resected. As with RFA, arrhythmia surgery has a potential role in patients with a prior MI and scar-associated reentrant circuits, but has little, if any, role in patients with a diffuse cardiomyopathy. Arrhythmia surgery was used more commonly prior to the advent of RFA, particularly in patients with a left ventricular aneurysm and sustained monomorphic VT. The successes of ICD implantation and RFA have made surgery for ventricular arrhythmias appropriate only in rare circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34503?source=see_link\">",
"     \"Surgery for ventricular tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cardiac transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac transplantation may be an option for patients with advanced HF who have experienced serious life-threatening ventricular tachyarrhythmias. In such patients, there may be a role for the ICD as a bridge to transplantation by preventing a fatal arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/24-28\">",
"     24-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential efficacy of this approach was illustrated in a report of 16 patients with a mean LVEF of 15 percent who were listed for heart transplantation and underwent ICD implantation for ventricular arrhythmias refractory to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/24\">",
"     24",
"    </a>",
"    ]. The ICD delivered appropriate shocks for tachyarrhythmias associated with near syncope in all but one of the patients; five had more than 10 shocks and three had five to nine shocks. Twelve patients underwent transplantation after a mean of 156 days.",
"   </p>",
"   <p>",
"    These outcomes are much better than seen in similar patients not treated with an ICD. In a review of consecutive heart transplant candidates, the mortality rate was 4.7 percent in 21 patients treated with an ICD compared to 57 percent in 58 survivors of SCD treated medically [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/25\">",
"     25",
"    </a>",
"    ]. A benefit from an ICD may also be seen in selected patients listed for cardiac transplantation who do not have an established indication (eg, nonsustained VT and syncope) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION OF SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because patients with HF and cardiomyopathy are at risk for malignant ventricular arrhythmias, and SCD is often the first presentation of a ventricular arrhythmia, there is interest in therapies for the primary prevention of SCD. As in secondary prevention, randomized clinical trials have established a clear role for ICD implantation in selected patients. In contrast, antiarrhythmic drugs other than beta blockers do not appear to improve outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Role of an ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of an ICD in the primary prevention of SCD among patients with HF and cardiomyopathy depends upon several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The severity of left ventricular (LV) dysfunction",
"     </li>",
"     <li>",
"      The severity of clinical HF",
"     </li>",
"     <li>",
"      The etiology of LV dysfunction (ie, ischemic or nonischemic cardiomyopathy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of SCD increases with the severity of both LV dysfunction and clinical HF. However, the risk of death due to other causes (eg, progressive HF) also increases with worsening HF and LV function. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Causes of death in HF'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic ICD implantation for the primary prevention of SCD reduces mortality in selected patients with ischemic cardiomyopathy. The indications for ICD implantation are largely derived from inclusion criteria of the major clinical trials. These trials will be briefly summarized here and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MADIT and MUSTT trials &ndash; The MUSTT and MADIT trials demonstrated that prophylactic use of an ICD reduces total mortality in selected patients with a prior MI and moderate-to-severe LV dysfunction. In MUSTT and MADIT-I, entry criteria included an LVEF &le;35 or 40 percent, NSVT, and inducible sustained VT at EP study [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. In the later MADIT-II trial, entry criteria included only an LVEF &le;30 (ie, there was no requirement for NSVT or an EP study) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients who would meet entry criteria for these trials are currently considered candidates for ICD therapy for primary prevention.",
"     </li>",
"     <li>",
"      SCD-HeFT trial &ndash; In the SCD-HeFT trial, 2521 patients with an LVEF &le;35 percent (median 25 percent) and NYHA class II or III HF (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) were randomly assigned to ICD therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/32\">",
"       32",
"      </a>",
"      ]. The cardiomyopathy was ischemic in 52 percent of the patients. At a median follow-up of 46 months, ICD therapy significantly reduced overall mortality compared to placebo (29 versus 36 percent overall, with a similar risk reduction in the patients with ischemic cardiomyopathy); in comparison, amiodarone therapy had no survival benefit. ICD therapy had no overall adverse effect on quality of life and was associated with a short-term improvement in psychological well-being [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of other variables have been evaluated for their ability to predict the risk of SCD in patients with a prior MI. These include late potentials on signal-averaged ECG (SAECG), reduced heart rate variability (HRV), and T wave or repolarization alternans (TWA). Although each of these variables is associated with arrhythmic risk, available data does not yet support incorporating them into the criteria for ICD implantation. The approach to risk stratification for SCD in ischemic cardiomyopathy is discussed detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nonischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who meet SCD-HeFT criteria, including an LVEF &le;35 percent and NYHA class II to III (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) HF, we recommend ICD implantation. This recommendation is consistent with the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of criteria for the use of ICD therapy for primary prevention of SCD in patients with nonischemic cardiomyopathy has been more challenging than in patients with ischemic cardiomyopathy. Two reasons for this difficulty are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk stratification has proven more difficult. Many of the variables that are predictive of arrhythmic risk in patients with prior myocardial infarctions are not predictive in patients with nonischemic cardiomyopathy. In the Marburg Cardiomyopathy Study, for example, 343 patients with idiopathic dilated cardiomyopathy underwent prospective evaluation of multiple potential risk factors including LVEF, LV size, SAECG, NSVT, QT interval dispersion, HRV, baroreflex sensitivity, and TWA [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/34\">",
"       34",
"      </a>",
"      ]. At 52 months of follow-up, only LVEF was significantly associated with arrhythmia risk (relative risk [RR] 2.3 per 10 percent decrease in LVEF).",
"     </li>",
"     <li>",
"      Early clinical trials of ICD therapy in primary prevention did not include patients with nonischemic cardiomyopathy. This was due in part to the belief that patients with nonischemic cardiomyopathy were at such a high risk for nonarrhythmic death that an ICD would not produce an overall survival benefit. Furthermore, the initial trials of ICD therapy in patients with idiopathic or nonischemic cardiomyopathy (CAT and AMIOVIRT) showed no survival benefit, although they were limited by small sample size [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, larger trials and a meta-analysis have demonstrated survival benefit from prophylactic ICD implantation in selected patients with nonischemic cardiomyopathy. These trials are discussed in detail separately, but the magnitude of benefit can be illustrated by the findings in the large SCD-HeFT trial and a meta-analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SCD-HeFT trial cited above, 2521 patients with an LVEF &le;35 percent (median 25 percent) and NYHA class II or III HF (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) were randomly assigned to ICD therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/32\">",
"       32",
"      </a>",
"      ]. The median LVEF was 25 percent and the cardiomyopathy was nonischemic in 48 percent of the patients. At a median follow-up of 46 months, ICD therapy significantly reduced overall mortality compared to placebo (29 versus 36 percent overall, with a similar risk reduction in the patients with nonischemic cardiomyopathy); in comparison, amiodarone therapy had no survival benefit. ICD therapy had no overall adverse effect on quality of life and was associated with a short-term improvement in psychological well-being [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of five trials with 1854 patients published before SCD-HeFT examined the use of an ICD for primary prevention in patients with a nonischemic cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/15\">",
"       15",
"      </a>",
"      ]. There was a significant reduction in all-cause mortality with an ICD compared to medical therapy (relative risk 0.69, 95% CI 0.55-0.87). Based upon the averaged control group mortality rate (7 percent per year), the absolute risk reduction was 2 percent per year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In January 2005, the Center for Medicare Services (CMS) in the United States approved coverage for ICD use for the primary prevention of SCD in patients with a nonischemic dilated cardiomyopathy for more than three months who have an LVEF &le;35 percent and NYHA class II or III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Exceptions included irreversible brain damage and noncardiac disease associated with a likelihood of survival of less than one year. Patients with nonischemic cardiomyopathy of three to nine months duration are covered for ICD implantation if they are enrolled in a clinical trial or registry. As the majority of patients undergoing ICD implantation in the United States are enrolled in the NCDR ICD registry, the \"waiting period\" after diagnosis of nonischemic cardiomyopathy is effectively three months.",
"   </p>",
"   <p>",
"    The three to nine month delay before approval prompted a post hoc analysis of the relationship between ICD benefit and duration of nonischemic cardiomyopathy in the DEFINITE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/39\">",
"     39",
"    </a>",
"    ]. The mortality benefit from an ICD was comparable in patients with recent onset cardiomyopathy (less than three months) and those who had the diagnosis for more than nine months.",
"   </p>",
"   <p>",
"    Thus, although the LVEF may improve with waiting, there is a risk of SCD during the first few months. Nevertheless, these observations have not changed the CMS guidelines, which govern Medicare reimbursement in the United States. A wearable defibrillator vest may be considered if ICD implantation is deferred. The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    practice guidelines do not specify any delay in ICD implantation after the diagnosis of nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for ICD therapy in patients with certain specific types of cardiomyopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=see_link\">",
"     \"Isolated left ventricular noncompaction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7723381\">",
"    <span class=\"h3\">",
"     Optimal medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to prophylactic placement of an ICD for primary prevention, patients should be treated with optimal medical therapy directed toward heart failure and the underlying cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/40\">",
"     40",
"    </a>",
"    ]. In most cases and in the absence of a contraindication, optimal medical therapy for such patients would include use of a beta blocker along with either an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB). A detailed discussion regarding the choice of heart failure therapies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a 2011 study analyzing 175,757 first-time ICD recipients, using data from the National Cardiovascular Data Registry, 25.7 percent of ICD recipients without a documented contraindication were not receiving optimal medical therapy at the time of ICD implantation, including 18.7 percent who were not receiving an ACE inhibitor or ARB and 10.7 percent who were not receiving a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/41\">",
"     41",
"    </a>",
"    ]. These data suggest an opportunity for significant improvement in the treatment of patients with evidence-based, cost-effective therapies that could potentially result in improvement in cardiomyopathy and avoidance of an ICD.",
"   </p>",
"   <p>",
"    For patients who meet criteria for insertion of an ICD for the primary prevention of sudden cardiac death, in the absence of a contraindication, we recommend optimizing medical therapy with a beta blocker and either an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker",
"    <strong>",
"     PRIOR",
"    </strong>",
"    to ICD implantation. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     ICD combined with CRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with an LVEF &le;35 percent, class III or IV HF, and a QRS duration &ge;120 msec, we recommend implantation of a combined CRT-D device (BiV pacing combined with an ICD). This recommendation is consistent with the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities (as well as the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of chronic HF) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/6,42\">",
"     6,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients with HF and cardiomyopathy, the loss of myocardial contractile function is exacerbated by the development of ventricular dyssynchrony. Ventricular dyssynchrony refers to the loss of coordinated contraction across the left ventricle, which can further impair the pump function of a failing ventricle, resulting in worse HF symptoms.",
"   </p>",
"   <p>",
"    Cardiac resynchronization therapy (CRT) with biventricular (BiV) pacing can improve pump performance, reverse the deleterious process of ventricular remodeling, and improve survival in appropriately selected patients. CRT can be achieved with a device designed for pacing only (CRT-P) or can be incorporated into a combination device with ICD capabilities (CRT-D). There is some evidence that CRT-P alone may reduce the risk of SCD, probably by ameliorating the severity of HF. However, there is a more dramatic reduction in both SCD and total mortality with combined CRT-D devices. A detailed discussion of CRT is presented separately, but the results of two major trials (CARE HF and COMPANION) will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CARE HF trial evaluated the role of CRT-P (ie, BiV pacing without an ICD) in patients with severe cardiomyopathy and advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/43\">",
"     43",
"    </a>",
"    ]. At a mean follow up of 29 months, CRT-P reduced total mortality compared to standard medical therapy (20 versus 30 percent). The decrease in mortality was largely due to a reduction in deaths due to worsening HF (8.1 versus 13.9 percent). There was a lesser reduction in deaths classified as sudden (7.1 versus 9.4 percent), suggesting that the outcomes might be further improved with CRT-D.",
"   </p>",
"   <p>",
"    This hypothesis was supported by the COMPANION trial, which randomly assigned 1520 patients to optimal medical therapy, CRT-P, or CRT-D (BiV pacing with an ICD) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/44\">",
"     44",
"    </a>",
"    ]. At twelve months, there was a significant reduction in the incidence of the combined end point of all-cause mortality and all-cause hospitalization in the two arms receiving CRT compared to the medical therapy only arm (56 versus 68 percent) (",
"    <a class=\"graphic graphic_figure graphicRef78949 \" href=\"UTD.htm?38/42/39597\">",
"     figure 1",
"    </a>",
"    ). The CRT-D arm, but not the CRT-P arm, experienced a significant improvement (36 percent) in the secondary end point of all-cause mortality alone.",
"   </p>",
"   <p>",
"    Based upon the results of the COMPANION trial, the United States Food and Drug Administration approved the use of combination devices (CRT-D) in patients who meet criteria for a BiV pacemaker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link&amp;anchor=H19#H19\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'ICD combined with CRT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Class IV HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class IV HF is a state that may be transitory and therefore associated with heterogeneous prognosis. Once Class IV HF is refractory (Stage D HF), (",
"    <a class=\"graphic graphic_algorithm graphicRef57809 \" href=\"UTD.htm?1/38/1637\">",
"     algorithm 1",
"    </a>",
"    ), life expectancy is generally less than one year, unless cardiac transplantation is performed. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cardiac transplantation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The role of ICD therapy for primary prevention of SCD in patients with NYHA class IV HF with a narrow QRS complex has not been studied. However, a nonrandomized series of patients awaiting cardiac transplantation suggested a higher likelihood of survival to transplantation with ICD therapy, regardless of whether the ICD indication was well established [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these considerations, for patients with NYHA class IV HF, an LVEF &le;35 percent and a narrow QRS complex (ie, no dyssynchrony), who have a reasonable likelihood of survival for &ge;1 year or are awaiting cardiac transplantation, we suggest ICD implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients were men in the randomized trials that established the efficacy of ICDs. A meta-analysis was performed to study outcomes in women using pooled data from five randomized controlled trials of ICD implantation for primary prevention of SCD in patients with HF and reduced LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/45\">",
"     45",
"    </a>",
"    ]. The study found no significant decrease in all-cause mortality in women receiving ICDs (HR 1.01; 95% CI, 0.76-1.33). However, the hazard ratio for women overlapped with that for men (HR 0.78; 95% CI, 0.70-0.87), and differences between men and women were not consistent across studies, so an effect of chance cannot be excluded.",
"   </p>",
"   <p>",
"    Given the limitations of available data including the meta-analysis, we recommend that women should continue to receive ICD therapy for primary prevention according to standard guideline recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Older adults and patients with comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older adults and patients with major comorbidities have been underestimated in major ICD trials. Because of the risks of noncardiac death, some older adults and those with multiple or severe comorbidities may be less likely to derive benefit from an ICD.",
"   </p>",
"   <p>",
"    A retrospective cohort study of the clinical effectiveness of ICDs was conducted in a cohort of 4685 Medicare beneficiaries with HF and LVEF &le;35 percent. Mean age was 75.2 years and 376 (8 percent) received an ICD before discharge.",
"   </p>",
"   <p>",
"    This issue is further discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H7#H7\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'Impact of age and comorbidities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Prognostic significance of ICD shocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with HF receiving ICDs for primary prevention in the SCD-HeFT trial, receipt of an appropriate shock, as compared to no appropriate shock, was associated with substantially increased all-cause mortality (hazard ratio, 5.7; 95% CI 4.0 to 8.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/46\">",
"     46",
"    </a>",
"    ]. Receipt of an inappropriate shock, as compared with no inappropriate shock, was also associated with a significant increase in mortality (hazard ratio, 2.0, 95% CI, 1.3 to 3.1). The most common cause of death among patients who received any ICD shock was progressive HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized clinical trials do NOT support the routine use of prophylactic antiarrhythmic drug therapy, other than beta blockers, to prevent SCD in patients with HF. The lack of overall benefit from prophylactic antiarrhythmic drug therapy is due to both incomplete suppression of ventricular arrhythmias and the risk of proarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/47-51\">",
"     47-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the antiarrhythmic drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    has the advantage of a relatively low rate of proarrhythmia. Initial trials, such as GESICA, and a meta-analysis of 13 randomized trials, suggested both a mortality and an SCD benefit from amiodarone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, other trials, such as CHF-STAT, found neither a mortality nor an SCD benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/54\">",
"     54",
"    </a>",
"    ]. Furthermore, the largest single trial, SCD-HeFT, showed that mortality was not reduced by amiodarone therapy compared to placebo&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of chronic HF do NOT recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    for the prevention of SCD in this setting, but concluded that the evidence was in favor of efficacy for its use for the management of atrial arrhythmias or for reducing the frequency of ICD shocks in patients with recurrent ventricular arrhythmias (",
"    <a class=\"graphic graphic_table graphicRef80859 \" href=\"UTD.htm?41/45/42716\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other drugs have been evaluated in patients with HF; other than beta blockers, none improves mortality and each has a risk of proarrhythmia, which significantly limits the use of these drugs in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers &mdash; Beta blockers are a standard therapy for HF, if tolerated, because they significantly improve survival (",
"      <a class=\"graphic graphic_figure graphicRef78949 \" href=\"UTD.htm?38/42/39597\">",
"       figure 1",
"      </a>",
"      ). This benefit is achieved in part by a reduction in SCD (eg, 3.9 versus 6.6 percent in MERIT-HF and 3.6 versus 6.3 percent in CIBIS-II) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/2,55\">",
"       2,55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      &mdash; Prophylactic dofetilide in the DIAMOND-CHF trial of patients with symptomatic HF reduced the incidence of atrial fibrillation but had no effect on mortality (41 versus 42 percent with placebo) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"       \"Atrial fibrillation in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Azimilide &mdash; Among patients with ischemic cardiomyopathy in the ALIVE trial, most of whom had symptomatic HF, azimilide reduced the incidence of atrial fibrillation but had no effect on mortality compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/57\">",
"       57",
"      </a>",
"      ]. Another trial of patients with an ICD showed a significant reduction in appropriate shocks among those treated with azimilide [",
"      <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both azimilide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , like some other antiarrhythmic drugs, have been associated with QT prolongation and torsades de pointes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link\">",
"     \"Therapeutic use of dofetilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the management of ventricular arrhythmias in patients with heart failure (HF) and cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     General HF therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HF and ventricular arrhythmias should be treated aggressively for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition to improving symptoms and survival, such therapy can reduce ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations for implantable cardioverster-defibrillator (ICD) implantation for the primary prevention of sudden cardiac death (SCD) vary according to the etiology of the cardiomyopathy (ie, ischemic or nonischemic cardiomyopathy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Ischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic ICD implantation reduces the risk of SCD in selected patients with a prior MI and impaired LV function. The indications for an ICD in patients with an ischemic cardiomyopathy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H26#H26\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Nonischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with nonischemic cardiomyopathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who meet criteria for insertion of an ICD for the primary prevention of sudden cardiac death, in the absence of a contraindication, we recommend optimizing medical therapy with a beta blocker and either an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker",
"      <strong>",
"       PRIOR",
"      </strong>",
"      to ICD implantation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7723381\">",
"       'Optimal medical therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H27823757#H27823757\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'SUMMARY AND RECOMMENDATIONS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who meet SCD-HeFT criteria, including an LVEF &le;35 percent and NYHA class II to III (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) HF, we recommend ICD implantation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Nonischemic cardiomyopathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link&amp;anchor=H8#H8\">",
"       \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'SCD-HeFT trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with an LVEF &le;35 percent, class III or IV HF, and a QRS duration &ge;120 msec, we recommend implantation of a combined CRT-D device (BiV pacing combined with an ICD) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'ICD combined with CRT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with NYHA class IV HF, an LVEF &le;35 percent and a narrow QRS complex (ie, no dyssynchrony), who have a reasonable likelihood of survival for &ge;1 year or are awaiting cardiac transplantation, we suggest ICD implantation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cardiac transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts recommend ICD implantation in selected patients who do not meet the above criteria. In particular, the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines suggest ICD implantation could be considered, although the weight of evidence was less well established, for patients with nonischemic cardiomyopathy, an LVEF &le;35 percent, and NYHA class I HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/55/19322/abstract/6\">",
"     6",
"    </a>",
"    ]. As direct clinical trial data in this subgroup are not available, and the balance of risks and benefits of ICD implantation in this population is uncertain, we suggest that ICDs",
"    <strong>",
"     not",
"    </strong>",
"    be implanted routinely in such patients (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HF and cardiomyopathy who survive an episode of SCD or have symptomatic ventricular tachycardia (VT) are typically treated with an ICD for secondary prevention. The indications for ICD implantation for the secondary prevention of SCD are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Unexplained syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have shown a high risk of mortality and SCD in patients with severe HF and LV dysfunction and unexplained syncope.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with nonischemic cardiomyopathy, an LVEF &le;30 percent and unexplained syncope, we suggest ICD implantation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Patients with syncope'",
"      </a>",
"      above.) Patients with an ischemic cardiomyopathy and an LVEF &le;30 percent already qualify for an ICD based upon the results of the MADIT-II trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best approach for managing patients with an LVEF &gt;30 percent and unexplained syncope is not clear, and likely varies according to the etiology of the cardiomyopathy. For such patients with an ischemic cardiomyopathy, we perform an EP study, and if the patient has inducible VT, implant an ICD. For patients with a nonischemic cardiomyopathy, EP study is less informative, although they may reveal conduction abnormalities or bundle branch reentrant VT. In such patients, decisions regarding ICD implantation are often empiric and individualized, based upon the nature of the history (eg, how suggestive the event is for a tachyarrhythmia), the degree of LV dysfunction, as well as patient preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiarrhythmic drugs, radiofrequency ablation, and arrhythmia surgery have all been evaluated for their ability to reduce arrhythmia recurrence and improve survival in patients with HF, cardiomyopathy, and ventricular arrhythmias. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Other treatment options'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    None of these treatments is an adequate alternative to ICD implantation for the purpose of primary or secondary prevention of SCD in high-risk patients. These therapies, however, have a limited role in selected patients, usually in one of three settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an adjunct to ICD therapy to suppress recurrent ventricular arrhythmias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"       \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As an alternative to an ICD in patients who do not want or are not candidates for an ICD.",
"     </li>",
"     <li>",
"      For the control of symptoms due to frequent nonsustained ventricular arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific recommendations for the use of these therapies in a variety of settings are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link\">",
"     \"Management of nonsustained ventricular tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/1\">",
"      Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996; 17:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/2\">",
"      Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/3\">",
"      Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/4\">",
"      Greenberg H, Case RB, Moss AJ, et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/5\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/6\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/7\">",
"      Tchou PJ, Kadri N, Anderson J, et al. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med 1988; 109:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/8\">",
"      Fogoros RN, Elson JJ, Bonnet CA, et al. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol 1990; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/9\">",
"      Powell AC, Fuchs T, Finkelstein DM, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993; 88:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/10\">",
"      Kim SG, Maloney JD, Pinski SL, et al. Influence of left ventricular function on survival and mode of death after implantable defibrillator therapy (Cleveland Clinic Foundation and Montefiore Medical Center experience). Am J Cardiol 1993; 72:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/11\">",
"      Kuck KH, Cappato R, Siebels J, R&uuml;ppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/12\">",
"      Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/13\">",
"      A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/14\">",
"      Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/15\">",
"      Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292:2874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/16\">",
"      Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003; 41:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/17\">",
"      Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993; 21:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/18\">",
"      Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol 2000; 85:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/19\">",
"      Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol 1999; 33:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/20\">",
"      Grimm W, Hoffmann J J&uuml;, M&uuml;ller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 2002; 39:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/21\">",
"      Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001; 142:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/22\">",
"      Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999; 340:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/23\">",
"      Soejima K, Stevenson WG, Sapp JL, et al. Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy: the importance of low-voltage scars. J Am Coll Cardiol 2004; 43:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/24\">",
"      Jeevanandam V, Bielefeld MR, Auteri JS, et al. The implantable defibrillator: an electronic bridge to cardiac transplantation. Circulation 1992; 86:II276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/25\">",
"      Grimm M, Wieselthaler G, Avanessian R, et al. The impact of implantable cardioverter-defibrillators on mortality among patients on the waiting list for heart transplantation. J Thorac Cardiovasc Surg 1995; 110:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/26\">",
"      Bolling SF, Deeb GM, Morady F, et al. Automatic internal cardioverter defibrillator: a bridge to heart transplantation. J Heart Lung Transplant 1991; 10:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/27\">",
"      Lorga-Filho A, Geelen P, Vanderheyden M, et al. Early benefit of implantable cardioverter defibrillator therapy in patients waiting for cardiac transplantation. Pacing Clin Electrophysiol 1998; 21:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/28\">",
"      Saba S, Atiga WL, Barrington W, et al. Selected patients listed for cardiac transplantation may benefit from defibrillator implantation regardless of an established indication. J Heart Lung Transplant 2003; 22:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/29\">",
"      Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/30\">",
"      Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/31\">",
"      Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/32\">",
"      Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/33\">",
"      Mark DB, Anstrom KJ, Sun JL, et al. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008; 359:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/34\">",
"      Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003; 108:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/35\">",
"      B&auml;nsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/36\">",
"      Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J Am Coll Cardiol 2003; 41:1707.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare and Medicaid Services. Summary of coverage for implantable cardioverter defibrillators (ICDs) as of January 27, 2005 www.cms.hhs.gov/mcd/viewimplementation.asp?id=148 (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/38\">",
"      McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med 2005; 352:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/39\">",
"      Kadish A, Schaechter A, Subacius H, et al. Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol 2006; 47:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/40\">",
"      Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/41\">",
"      Miller AL, Wang Y, Curtis J, et al. Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry. Arch Intern Med 2012; 172:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/42\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/43\">",
"      Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/44\">",
"      Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/45\">",
"      Ghanbari H, Dalloul G, Hasan R, et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med 2009; 169:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/46\">",
"      Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/47\">",
"      Pratt CM, Eaton T, Francis M, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989; 118:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/48\">",
"      Hallstrom A, Pratt CM, Greene HL, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol 1995; 25:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/49\">",
"      Slater W, Lampert S, Podrid PJ, Lown B. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 1988; 61:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/50\">",
"      Gottlieb SS, Kukin ML, Medina N, et al. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation 1990; 81:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/51\">",
"      Ravid S, Podrid PJ, Lampert S, Lown B. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol 1989; 14:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/52\">",
"      Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/53\">",
"      Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/54\">",
"      Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/55\">",
"      The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/56\">",
"      Torp-Pedersen C, M&oslash;ller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/57\">",
"      Camm AJ, Pratt CM, Schwartz PJ, et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/55/19322/abstract/58\">",
"      Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2004; 43:39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 946 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19322=[""].join("\n");
var outline_f18_55_19322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF DEATH IN HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Guideline recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SECONDARY PREVENTION OF SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Use of an ICD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Patients with syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - SCD despite ICD implantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other treatment options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Arrhythmia surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PRIMARY PREVENTION OF SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Role of an ICD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nonischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7723381\">",
"      - Optimal medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - ICD combined with CRT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Class IV HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Older adults and patients with comorbidities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Prognostic significance of ICD shocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      General HF therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Nonischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Unexplained syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/946\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/946|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/38/1637\" title=\"algorithm 1\">",
"      Stages evolution HF and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/946|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/42/39597\" title=\"figure 1\">",
"      Mortality metoprolol HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/946|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/45/42716\" title=\"table 2\">",
"      ACC AHA Rx HF other diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=related_link\">",
"      Bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=related_link\">",
"      Isolated left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=related_link\">",
"      Management of nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34503?source=related_link\">",
"      Surgery for ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_55_19323="OP trauma symptoms";
var content_f18_55_19323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Concerning symptoms after oropharyngeal trauma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms suggesting deep neck infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neck pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Torticollis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New onset of drooling or dysphagia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased neck swelling or bleeding from the mouth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms suggesting cerebral artery thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altered mental status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slurred or confused speech",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arm or leg weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clumsy gait or excessive falling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19323=[""].join("\n");
var outline_f18_55_19323=null;
var title_f18_55_19324="Monoamine oxidase inhibitor";
var content_f18_55_19324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monoamine oxidase inhibitors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade name*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furazolidone",
"       </td>",
"       <td>",
"        Furoxone",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Antimicrobial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isocarboxazid",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Marplan",
"       </td>",
"       <td>",
"        Antidepressant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linezolid",
"       </td>",
"       <td>",
"        Zyvox",
"       </td>",
"       <td>",
"        Antimicrobial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moclobemide",
"       </td>",
"       <td>",
"        Manerix",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Antidepressant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pargyline",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Eutonyl",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Antidepressant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenelzine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Nardil",
"       </td>",
"       <td>",
"        Antidepressant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procarbazine",
"       </td>",
"       <td>",
"        Matulane",
"       </td>",
"       <td>",
"        Antineoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rasagiline",
"       </td>",
"       <td>",
"        Azilect",
"       </td>",
"       <td>",
"        Parkinson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selegiline",
"       </td>",
"       <td>",
"        Eldepryl",
"       </td>",
"       <td>",
"        Parkinson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selegiline transdermal patch",
"       </td>",
"       <td>",
"        Emsam",
"       </td>",
"       <td>",
"        Parkinson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tranylcypromine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Parnate",
"       </td>",
"       <td>",
"        Antidepressant",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Trade name in US and some other countries.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Not available in US.",
"     <br/>",
"     &Delta; Potent non-selective monoamine oxidase inhibitor requiring vigilant food and drug interaction monitoring or preferably discontinuation two to three weeks pre-operatively.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19324=[""].join("\n");
var outline_f18_55_19324=null;
var title_f18_55_19325="Simvastatin and CHD mortality";
var content_f18_55_19325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Simvastatin improves survival in hypercholesterolemic patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 252px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Overall survival in 4444 subjects with established coronary heart disease and a plasma cholesterol concentration between 212 and 309 mg/dL (5.5 to 8.0 mmol/L) who were treated with simvastatin or placebo. Simvastatin led to a significant improvement in patient survival (p&lt;0.003).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pedersen, TR, and the Scandinavian Simvastatin Survival Study Group, Lancet 1994; 344:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19325=[""].join("\n");
var outline_f18_55_19325=null;
var title_f18_55_19326="Activation of G proteins";
var content_f18_55_19326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Activation of G proteins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 273px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upon binding of hormone to the receptor, a change occurs in the structure of the hormone-receptor complex such that a G-protein is recruited to the membrane and activated. G-proteins are composed of three subunits (alpha, beta and gamma). G-protein stimulation then initiates a variety of cellular processes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael A Shetzline, MD, PhD and Rodger A Liddle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19326=[""].join("\n");
var outline_f18_55_19326=null;
var title_f18_55_19327="Knee dislocatn ant1";
var content_f18_55_19327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior knee dislocation with PCL intact",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral knee radiograph above shows an anterior knee dislocation with the posterior cruciate ligament (PCL) intact. Note the parallel alignment of the patellofemoral joint with the femur in the complete bicruciate injury and the close proximity of the femur and tibia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed. Lippincott, Williams &amp; Wilkins, 2001. Copyright &copy; Lippincott, Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_55_19327=[""].join("\n");
var outline_f18_55_19327=null;
